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BCR-ABL is the oncogenic protein-tyrosine kinase responsible for the pathogenesis of chronic 
myelogenous leukemia (CML). Clinical management of CML has been revolutionized by 
imatinib, a selective ATP-competitive inhibitor of BCR-ABL kinase activity. Despite this 
clinical success, imatinib is less effective in advanced disease due to the emergence of drug 
resistant BCR-ABL mutants. Resistant mutations often arise in the drug binding site and include 
the most recalcitrant gatekeeper mutation, T315I. Other mutations arise outside the active site 
and allosterically reduce imatinib binding by promoting the active kinase conformation. 
Recently, a new class of allosteric BCR-ABL inhibitors, of which GNF-2 is the prototype, has 
been reported that targets the myristate-binding pocket of ABL. These compounds stabilize the 
inactive conformation of ABL and work in concert with ATP-competitive inhibitors to overcome 
imatinib resistance. Mounting evidence supports a regulatory influence of the non-catalytic SH3 
and SH2 domains on BCR-ABL kinase domain. The major focus of this study was to exploit the 
intramolecular SH3:linker interaction, to stabilize the downregulated kinase domain 
conformation of BCR-ABL and sensitize the kinase to both imatinib and GNF-2. To achieve this 
goal, I engineered High Affinity Linker (HAL) variants of both ABL and BCR-ABL in which 
SH3:linker interaction was tightened through sequential addition of proline residues to the linker. 
Enhanced SH3:linker interaction induced long-range suppressive effects on the kinase activity in 
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c-ABL, allosterically stabilized both the active site and the myristate-binding pocket, and 
sensitized BCR-ABL to small molecule inhibitors.  
Src family kinases (SFKs) are important mediators of BCR-ABL signal transduction and 
oncogenesis in CML. SFKs also play important roles in clinical resistance to imatinib in the 
absence of BCR-ABL mutations. In the second part of my project, I explored the effect of SFK- 
selective inhibitor, pyrazolopyrimidine A-419259, on myeloid cells transformed with clinically 
relevant imatinib resistant BCR-ABL mutants. While proliferation of cells expressing BCR-ABL 
E255V and Y253H was inhibited by A-419259, BCR-ABL T315I cells were not. Surprisingly, 
cells expressing BCR-ABL-T315I maintained SFK activity in the presence of the inhibitor. This 
observation suggests that BCR-ABL-T315I induces cross-resistance to drugs that inhibit SFKs in 
CML through direct phosphorylation of the SFKs. 
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1.0  INTRODUCTION 
1.1 THE DISCOVERY OF PHILADELPHIA CHROMOSOME AND THE CLONAL 
EVOLUTION OF CANCER HYPOTHESIS 
In the early nineteen hundreds and even prior to the determination of human chromosome 
number, Theodore Boveri proposed that tumors result from chromosomal abnormalities that 
originate in a single cell. The tumor is thus characterized as a genetically unstable cell population 
that is unresponsive to growth regulation. This hypothesis was later developed and supported as 
the “clonal evolution” model for tumor development (Boveri, 2008; Nowell, 2007). 
With the advancement of cell and tissue culture techniques, the human chromosome 
number was determined. Furthermore, chromosomal abnormalities were shown to be associated 
with certain human disorders such as Down syndrome (Harper, 2006). However, the association 
between specific chromosomal alteration and cancer was made for the first time by David 
Hungerford and Peter Nowell in 1960 (Nowell, 1962; Nowell, 2007). They identified a 
characteristic minute chromosome in neoplastic cells from chronic myelogenous leukemia 
(CML) patients. This minute chromosome was designated as the “Philadelphia (Ph) 
Chromosome” because it was discovered at the University of Pennsylvania School of Medicine 
in Philadelphia, where Dr. Nowell was a member of the Pathology faculty. In 1973, Janet 
Rowley discovered that the Ph chromosome arises from a reciprocal translocation between 
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chromosome 9 and chromosome 22 (Rowley, 1980). In the 1980s, John Groffen and Nora 
Heisterkamp showed that the Ph chromosome translocation, now known as t(9;22)(q34;q11), 
fuses the “breakpoint cluster region gene” (BCR) on chromosome 22 with sequences of the c-
ABL proto-oncogene on chromosome 9. This fusion generates the BCR-ABL oncogene that 
encodes the constitutively active chimeric BCR-ABL protein (Lugo et al., 1990; Heisterkamp 
and Groffen, 2002) . There are three BCR-ABL variants that are associated with different types 
of leukemias (Figure 1). The three variants arise from differences in the position of the 
translocation, which affects the length of the BCR gene fused to ABL sequences. Splicing at the 
minor (m), major (M) or micro (µ) breakpoints in BCR produces three distinct proteins, p185, 
p210 and p230 respectively. The three variants differ in the amount of the BCR portion of the 
protein and are involved in acute lymphocytic leukemia (p185), chronic myelogenous leukemia 
(p210) and chronic neutrophilic leukemia (p230) (Lugo et al., 1990; Voncken et al., 1995; 
Advani and Pendergast, 2002).  Work described in this thesis is related exclusively to the p210 
form of BCR-ABL which is associated with more than 95% of CML cases. 
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Abl
SH3 SH2 N-lobe C-lobe Last exon ABDPHDHS/T kinaseCC
Bcr
p210 Bcr-Abl
SH3-SH2 
connector SH2-kinase 
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A 
B 
C
 
Figure 1: BCR-ABL variants. A) BCR and ABL genes and the site of the breakpoints in each are marked by the 
arrows. B) Chimeric BCR-ABL mRNA transcripts. C) Functional domain organizations of the chimeric p210 BCR-
ABL protein. The BCR portion is composed of the following regions: CC: coiled-coil motif, S/T kinase: serine-
threonine kinase, DH: Dbl homology domain, PH: pleckstrin homology domain. The ABL portion consists of SH3: 
Src homology domain 3, SH3-SH2 connector, SH2: Src homology domain 2, SH2-kinase linker, Tyrosine kinase 
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domain composed of an N-lobe and C-lobe, Last exon region composed of nuclear localization and export signals, 
proline rich regions (PxxP) capable of binding to SH3 domains, DNA binding domains, and ABD: actin binding 
domain. Adapted from (Inokuchi, 2006; Pendergast, 2002; Ren, 2005). 
1.2 CML: CLINICAL COURSE, DISEASE INCIDENCE, MORTALITY AND 
SURVIVAL 
CML is a clonal disorder that results from neoplastic transformation of hematopoietic stem cells. 
The presence of the Ph chromosome is the cytogenetic hallmark of this disease. The Ph 
chromosome encodes a constitutively active protein-tyrosine kinase known as BCR-ABL (p210 
form) that drives CML pathogenesis through downstream signaling pathways promoting cell 
growth and survival (Sawyers, 1999; Wong and Witte, 2004; Nowell, 1962; Shtivelman et al., 
1985; Groffen et al., 1984). The causal relationship between the expression of BCR-ABL and 
CML is well established by several experimental models. For example, retroviral transduction of 
murine bone marrow with p210 BCR-ABL oncogene was shown to induce myeloproliferative 
disease (MPD) in mice that resembled CML (Daley et al., 1990; Kelliher et al., 1990). 
Furthermore, the efficiency of MPD induction was increased when the p210 BCR-ABL oncogene 
was specifically expressed in hematopoietic stem or progenitor cells (Pear et al., 1998).  In 
addition, studies using inducible expression of BCR-ABL in transgenic mice showed that mice 
developed a chronic phase CML like disease (Koschmieder et al., 2005). 
CML is a rare disease and accounts for about 20% of all leukemias. It occurs at a similar 
frequency in different countries around the world. The annual incidence rate is 1.6 cases per 
100,000 adults. The estimated number of new cases in the United States in 2012 is 5,430 and the 
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estimated deaths around 610. The median age at diagnosis is about 55 years (American Cancer 
Society, 2012). 
Clinically, CML has a triphasic course and is usually diagnosed during the early chronic 
phase of the disease. The chronic phase is characterized by expansion of cells of the granulocytic 
lineage that retain their ability to differentiate. Most patients are diagnosed at this stage as a 
result of an increased number of mature granulocytes in the peripheral blood, weight loss and 
splenomegaly. This phase lasts approximately 5 years on average and then the disease progresses 
to the accelerated phase and the blast crisis phase. These later phases are characterized by the 
accumulation of immature blasts in the bone marrow and the peripheral blood and loss of 
hematopoietic cell differentiation. Phenotypically, the majority of the patients (~80%) enter a 
myeloid blast stage resembling acute myeloid leukemia (AML) and about 20% of the patients 
enter a stage similar to the acute lymphoid leukemia (B-ALL) (Kurzrock et al., 1988; Advani and 
Pendergast, 2002; Sawyers, 1999; Ren, 2005). 
Allogeneic transplantation of bone marrow cells is the only curative treatment for CML. 
However, as discussed later in section 1.8, there are limitations to transplantation in terms of 
available compatible donors, age as well as large variability in 5 year survival rate.  However, 
since BCR-ABL is required for the onset and maintenance of CML, it has become an ideal 
therapeutic target for long-term disease management.  Imatinib mesylate (Signal Transduction 
Inhibitor-STI571; Gleevec) is a derivative of 2-phenylaminopyrimidine and was discovered in a 
screen for inhibitors of the platelet-derived growth factor receptor tyrosine kinase (PDGF-R). In 
1996, Druker and colleagues showed that imatinib selectively inhibits the proliferation of BCR-
ABL positive cells in vitro and in vivo (Druker et al., 1996). In 2001, FDA approved imatinib as 
the frontline therapy for CML (Schwetz, 2001). Imatinib is well-tolerated and most chronic 
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phase CML patients attain significant hematologic and cytogenetic responses. The relatively low 
toxicity of imatinib may be attributed to its selectivity for BCR-ABL, which is derived in part 
from its remarkable preference for the inactive conformation of the ABL kinase domain as 
discussed in the next section. 
1.3 OVERVIEW OF C-ABL 
The Abelson family of non-receptor protein-tyrosine kinases consists of two members, c-ABL 
and the ABL-related gene (ARG) (Hanks, 2003). c-ABL interacts with multitude of cellular 
proteins including transcription factors, the DNA repair machinery, cell cycle regulators, 
phosphatases and other kinases, signaling adaptors and the cytoskeleton. By the virtue of these 
interactions, c-ABL functions in many cellular processes including F-actin remodeling, cell 
adhesion and motility, DNA damage responses, cell proliferation and survival (Colicelli, 2010; 
Pendergast, 2002). There are two splice variants of c-ABL that differ in their amino termini; c-
ABL 1b is myristoylated at the N-terminus while the splice variant c-ABL 1a is 19 amino acids 
shorter and not myristoylated (Shtivelman et al., 1986). Both forms of c-ABL have nuclear 
localization sequences, nuclear export signals, C-terminal actin binding domains and shuttle 
between nuclear and cytoplasmic compartments in a cell (Van Etten, 1999; Pendergast, 2002).  
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1.4 STRUCTURAL OVERVIEW OF THE C-ABL KINASE CORE 
The kinase core of the c-ABL protein has a domain organization similar to that of the Src-family 
kinases (SFKs), and is comprised of an SH3 domain, an SH2 domain, an SH2-kinase linker and a 
tyrosine kinase domain that spans about 300 amino acids and structurally is composed of two 
lobes: the smaller amino-terminal lobe (N-lobe) and a larger c-terminal lobe (C-lobe) (Hubbard 
et al., 1994; Knighton et al., 1991; Superti-Furga and Courtneidge, 1995).  However regions N-
terminal to the SH3 domain and C-terminal to the kinase domain are different in c-ABL vs. c-
SRC. At the N-terminus, c-ABL has an extended unique domain called the N-terminal “cap” 
(referred to hereafter as the NCap) while at the C-terminal end of the kinase domain there is a 
long cytoplasmic region called the last-exon region, which is important in subcellular 
localization and interaction of the protein with DNA, other SH3 containing proteins, and the 
actin cytoskeleton (Hantschel and Superti-Furga, 2004; Pendergast, 2002; Van Etten, 1999). 
Each of these key structural and regulatory elements is discussed in detail below.
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Figure 2: Domain Organization of ABL kinase. Top: Schematic domain organization of c-ABL 1b and c-ABL 1b 
core proteins: Ncap: N-terminal region, SH3: Src homology domain 3, SH2: Src homology domain 2, SH2-kinase 
linker (Linker), N-and C-lobe of tyrosine kinase domain, Last exon or c-terminal region, ABD: actin binding 
domain. Bottom X-ray crystal structure of c-ABL 1b core protein in the downregulated state (PDB 2FO0) is 
rendered as a ribbon on the lower left and with surface added on the right. The unstructured section of the 
myristoylated NCap (Myr) that engages the C-lobe of the kinase domain is shown as dotted line. Domains in the 
structure are color coded and correspond to the schematic in the top. 
 
1.4.1 N-Terminal Cap (NCap) 
The first exon and part of second exon of the human ABL1 gene encodes an 80-residue region 
called the “NCap”. The NCap is located N-terminal to the SH3 domain and is myristoylated at its 
N-terminus in ABL-1b (Pluk et al., 2002). Prior to the first crystal structure of the c-ABL-1b 
core protein, mutational studies suggested that the NCap region has a role in inhibiting the kinase 
activity because its loss leads to activation of the c-ABL kinase. When the first crystal structure 
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of the core of ABL (residues 1-531) was solved, it became evident that the N-terminal myristic 
acid group penetrates into a deep hydrophobic pocket of the C-lobe of the kinase domain (Nagar 
et al., 2003) (Figure 2). Binding of the myristoyl group into this pocket induces a bend in helix αI 
which is also important for docking of the SH2 domain onto C-lobe of the kinase. Myristoylation 
is critical to maintaining autoinhibited state of the kinase as a non-myristoylated mutant of ABL-
1b with a glycine to alanine mutation at position 2 (G2A) is highly active. Furthermore, when 
amino acids in the C-lobe pocket are replaced with bulkier or polar residues, the kinase is 
activated (Hantschel et al., 2003). Presumably, the myristoylated NCap is unable to interact with 
these C-lobe mutants.  In addition, these changes may allosterically influence the active site as 
described in more detail below. 
Besides the myristoyl moiety, the NCap has important contact points along the SH3-SH2 
surface that also maintain the autoinhibited state of the kinase. NCap residues Leu73 and Lys70 
are proximal to the first β strand of SH3 domain and when they are individually mutated to 
alanines, induce kinase activity (Hantschel et al., 2003; Pluk et al., 2002). In the first crystal 
structure of c-ABL core (Nagar et al., 2003), the entire NCap region connecting the myristoyl 
group to the SH3 domain was disordered. Subsequently a higher resolution crystal structure was 
solved with an ABL core protein that spanned residues 1-531 with an internal deletion of 
residues 15-56 (Nagar et al., 2006). This deletion was shown to be dispensable for maintaining 
effective regulation of kinase activity (Hantschel et al., 2003). In this newer structure, Ser69 in 
the NCap was observed to be phosphorylated and to make contact with the SH3-SH2 connector. 
ABL activity was increased when Ser69 was mutated to alanine but more so if mutated to 
glutamate (Nagar et al., 2006). In summary, the N-terminal myristoyl group of the NCap makes a 
key regulatory contact with the C-lobe of the kinase, while the C-terminal region of the NCap 
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spanning residues 65-80 contacts the SH2 surface and the SH3-SH2 connector. Thus, the NCap 
helps in clamping the SH3 and SH2 domains to the back of the kinase domain, favoring the auto-
inhibited state. 
1.4.2 SH3 domain 
Src homology 3 (SH3) domains are small protein modules of about 60 amino acids. The first 
structure of an SH3 domain was reported in 1992 for c-SRC (Yu et al., 1992). Subsequently, a 
high resolution x-ray crystal structure of ABL SH3 domain was solved (Musacchio et al., 1994).  
Like other SH3 domains, the ABL SH3 is comprised of two small anti-parallel β-sheets packed 
against each other forming a barrel-shaped structure. SH3 domains bind to proline-rich peptides 
or stretches in partner proteins that adopt polyproline type II (PP-II) helical conformations 
(Kuriyan and Cowburn, 1997; Pawson and Gish, 1992; Pawson and Schlessingert, 1993) and 
often exhibit repeats of proline residues to form the sequence PxxP (where x is often a 
hydrophobic amino acid). Though SH3 domains were primarily considered as binding domains, 
it is now evident that they play an essential role in regulating kinase activity. The ABL SH3 
domain plays a major role in keeping the kinase in its autoinhibited state by interacting with the 
amino-terminal lobe of the kinase domain as well the SH2-kinase linker through an atypical 
PxxP motif (P242TVY245) (Nagar et al., 2003). This interaction persists even in the absence of the 
kinase domain (Hochrein et al., 2006). Deletion or mutations of the SH3 domain enhance the 
transforming activity of c-ABL supporting a negative regulatory role for SH3 in kinase 
regulation (Franz et al., 1989; Mayer and Baltimore, 1994). Moreover phosphorylation of Tyr245 
in the SH2-kinase linker or mutation of Pro242 can increase kinase activity (Barila and Superti-
Furga, 1998; Brasher and Van Etten, 2000). Work from our laboratory also showed that 
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phosphorylation of ABL SH3 Tyr89 disturbs SH3:linker engagement and leads to enhanced ABL 
kinase activity and downstream signalling in the context of BCR-ABL (Chen et al., 2008b).  
1.4.3 SH2 domain   
Src homology 2 (SH2) domains are about 100 amino acids in length and participate in protein-
protein interactions through sequence-specific recognition of phosphotyrosine-containing 
sequences. Structurally, SH2 domains are composed of a central anti-parallel β-sheet flanked by 
α-helices on each side. This central β-sheet divides the domain into two functionally distinct 
pockets, one which binds the P-Tyr side chain and another for binding of the side chain of the 
third amino acid C-terminal to the P-Tyr residue (Ladbury et al., 1995; Smithgall, 1995; Kuriyan 
and Cowburn, 1997). In SFKs, the SH2 domain engages a conserved phosphotyrosine residue in 
the C-terminal tail and this intramolecular interaction is critical to downregulation of kinase 
activity (Huse and Kuriyan, 2002). In contrast to c-SRC, however, c-ABL lacks a C-terminal 
phosphotyrosine residue, and the SH2 domain is coupled directly to the C-lobe of the kinase 
domain through network of hydrogen bonding interactions. Binding of the myristoylated NCap 
to the C-lobe reorients kinase domain helix αI which helps in docking to the SH2 domain 
(Hantschel et al., 2003; Nagar et al., 2003; Nagar et al., 2006). Several mutations at the SH2-C-
lobe kinase interface, particularly of Tyr158, showed an increase in kinase activity demonstrating 
the importance of this interface in proper positioning of the SH2 domain and its contribution to 
downregulation of kinase activity (Hantschel et al., 2003). Furthermore, Small-angle X-ray 
Scattering (SAXS) analysis of a form of active ABL that is missing the NCap, myristoylation site 
and is mutated at two proline residues in the linker region (P242E, P249E), demonstrated that the 
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SH2 domain reorients itself to the N-lobe of the kinase and that this interaction may contribute to 
one active state of the protein (Nagar et al., 2006). 
1.4.4 SH2-Kinase Linker 
In c-ABL as well as SFKs the SH2-kinase linker forms a polyproline type II helix that serves as 
an internal ligand for the SH3 domain. This interaction is important in keeping the kinase in its 
downregulated form as describe above. Mutations disrupting SH3:linker interaction lead to 
kinase activation and enhance the transforming capability of both c-ABL and SFKs (Barila and 
Superti-Furga, 1998; Hantschel et al., 2003; Meyn, III et al., 2006; Briggs and Smithgall, 1999). 
Despite the overall structural similarities between SFKs and the c-ABL core, there are important 
differences in the SH2-kinase linker. The c-ABL SH2-kinase linker has a unique conformation 
created in part by the insertion of two residues (W254, E255) near the N-lobe of the kinase 
relative to SFKs.  Biophysical evidence supports the persistence of SH3:linker interaction in the 
absence of the kinase domain and shows that W254 and E255 are important in stabilizing the 
linker and promoting SH3:linker interaction. This is in contrast to the SFK HCK, where 
SH3:linker interaction does not occur in the absence of the kinase domain. These results suggest 
that SH3:linker interaction may have a more prominent role in regulating the c-ABL kinase 
activity relative to the SFKs (Chen et al., 2007; Hochrein et al., 2006; Lerner et al., 2005).  
1.4.5 Kinase domain 
Overall protein kinase domain structure is highly conserved among Ser/Thr and Tyr kinases 
(Hubbard et al., 1994; Knighton et al., 1991). The kinase domain functions in the catalytic 
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transfer of γ-phosphate from ATP onto serine, threonine or tyrosine residues in substrate proteins 
and peptides (Hanks et al., 1988). The relative orientation of the two lobes and conserved 
residues in the active site play a major role in the catalytic reaction and in the dynamic 
interconversion of the active and inactive conformations of the kinase. Structural studies of 
kinases solved to date show that while the active conformations of most protein kinases are quite 
similar, the conformations of the inactive states are more varied and distinct, which provide 
opportunities for selective inhibitor discovery (Nagar et al., 2002; Zhang et al., 2009). 
Structural analyses of the c-ABL kinase domain as well as the larger core protein 
described above revealed the structural basis of its regulation (Schindler et al., 2000; Nagar et al., 
2002). The N-lobe of c-ABL is composed of a 5-stranded antiparallel β-sheet and a single α-
helix called the αC helix. On the other hand, the C-lobe is mainly helical and contains the peptide 
substrate binding site and the catalytic loop (Cox et al., 1994). The two lobes contribute to the 
active site with important conserved residues. The loop connecting strands β1 and β2 in the N-
lobe forms the phosphate binding loop or P-loop. A conserved glutamate (Glu286) from helix αC 
forms an ion pair with Lys271 of the N-lobe. This pairing is important in coordinating the 
phosphate group of ATP and is conserved in virtually all protein kinase structures. The 
orientation of helix αC also plays a major role in determining the active vs. inactive 
conformations of the kinase domain. In the inactive c-SRC and cyclin-dependent kinase 
structures, the αC helix is rotated out of the active site such that the Glu-Lys ion pair is disrupted. 
However, the orientation of the αC helix is unchanged and this ion pair is maintained in inactive 
ABL. The C-lobe contributes to the active site through the activation loop, another structural 
feature common to most kinases, with a single tyrosine site (Tyr412) that undergoes 
autophosphorylation. Phosphorylation of Tyr412 in the ABL activation loop allows electrostatic 
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interaction with a neighboring arginine residue, stabilizing an ‘open’ conformation of the active 
site and allowing the access to the peptide substrate. In the inactive conformation, Tyr412 is not 
phosphorylated and forms a hydrogen bond with the critical catalytic aspartate (Asp363) instead. 
This interaction orients the activation loop into the active site and mimics the binding mode of 
substrates. N-terminal to the activation loop is a highly conserved aspartate-phenylalanine-
glycine (D381FG383) motif.  In active kinases including ABL, the aspartate of the DFG motif is 
oriented towards the active site to coordinate a catalytically important magnesium ion. In 
inactive ABL, unlike in inactive c-SRC, this aspartate residue is flipped away from the active 
site, removing the side chain of Asp381 from the site of Mg++ coordination (so called ‘DFG Out’ 
conformation). This DFG-out conformation accounts in part for the specificity of imatinib 
binding to ABL (Schindler et al., 2000; Nagar et al., 2002; Levinson et al., 2006a; Nagar, 2007).  
(This point is explained in more detail in Section 1.9.1, below). 
1.4.6 Last-exon region 
Despite the structural similarities with SFKs noted above, c-ABL has a unique C-terminal 
extension beyond the kinase domain. This region contains proline-rich motifs that serve as 
binding sites for SH3 containing adaptor proteins. It also contains binding sites for tumor 
suppressor proteins, RNA polymerase II, DNA and F-actin. It also contains three nuclear 
localization signals and one nuclear export signal which are important in the subcellular 
localization of the protein (Feller et al., 1994; Smith et al., 1999; Goga et al., 1995a; Baskaran et 
al., 1996; Van Etten et al., 1989; Van Etten et al., 1994). 
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1.5 REGULATION OF C-ABL BY PHOSPHORYLATION AND PROTEIN 
PARTNER BINDING 
The c-ABL protein is ubiquitously expressed and its activity is tightly regulated in cells. In the 
absence of activating stimuli, neither endogenous nor overexpressed c-ABL are phosphorylated 
(Brasher and Van Etten, 2000; Dorey et al., 2001). The crystal structures of the downregulated c-
ABL core protein as well as biochemical studies revealed the key intramolecular interactions that 
are involved in regulating kinase activity. When these inhibitory intramolecular interactions are 
disrupted, phosphotyrosine content is increased which is positively correlated with activity 
(Barila and Superti-Furga, 1998). Thus phosphorylation at several tyrosine residues is crucial for 
regulation of ABL activity. Phosphorylation of Tyr412 in the activation loop is necessary to 
stabilize the active kinase activation as described in the previous section. This residue can 
undergo both autophosphorylation as well as trans-phosphorylation by other tyrosine kinases 
such as members of the SRC family. Mutation of this residue to phenylalanine impairs kinase 
activation (Brasher and Van Etten, 2000).  Along with Tyr412, Tyr245 in the SH2-kinase linker 
contributes to the full activation of the kinase and mutation of this site inhibits maximal 
activation of c-ABL by about 50% in vitro (Brasher and Van Etten, 2000). Other 
phosphorylation sites implicated in c-ABL regulation include Tyr134 in the SH3 domain which 
is involved in binding to SH2-kinase linker. Phosphorylation of this residue is predicted to 
interfere with the proper interaction of the SH3 domain with the linker. Tyr238 in the N-lobe and 
Ser94 in the SH3 domain are two other residues that come into close proximity. Phosphorylation 
of these residues may interfere with the packing of the SH3 against the N-lobe of the kinase 
domain and disturb the inhibitory intramolecular interactions (Brasher et al., 2001). Furthermore, 
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phosphorylation of SH3 Tyr89 interferes with linker binding, thereby disrupting negative 
regulatory interaction and leading to kinase activation (Chen et al., 2008b). 
Besides regulation by phosphorylation, c-ABL is also regulated through tyrosine 
phosphatases. Upon stress stimuli, SH3 domain of c-ABL interacts with SH3 binding motif in 
the catalytic domain of PTPN6 (also known as SHP-1). Overexpression of PTPN6 has also been 
implicated in reduction of the transforming potential of K562 cells, which were derived from a 
blast crisis CML patient and are p210 BCR-ABL-positive. PTPN12 and PTPN18 also 
dephosphorylate ABL and suppress its function (Kharbanda et al., 1996; Bruecher-Encke et al., 
2001; Cong et al., 2000). 
ABL is also regulated by interacting partners (Colicelli, 2010), and the interaction 
mechanisms are often complex. ABL may interact with other proteins through its SH2 or SH3 
domains via phosphotyrosine sites or PxxP motifs within the interacting partner, respectively. 
Conversely, SH2 or SH3 domains on partner proteins may associate with their respective 
phosphotyrosine sites and PxxP motifs on ABL. Interactions may also occur through other 
binding motifs in the C-terminal region of the protein. One class of ABL-binding proteins 
include the ABL interactor proteins ABI1 and ABI2, which bind to the C-terminal region of 
ABL through their SH3 domains and also interact with ABL SH3 domain through their PxxP 
motifs. ABI1 binding enhances phosphorylation of ABL substrates and facilitates ABL 
oligomerization and autophosphorylation (Dai and Pendergast, 1995; Shi et al., 1995; Xiong et 
al., 2008). In the context of BCR-ABL expressing cells, ABI2 undergoes ubiquitin-dependent 
degradation while ABI1 does not (Li et al., 2007). ABI1 is phosphorylated and is a downstream 
substrate of BCR-ABL in hematopoietic cells. There is increasing evidence to support the role of 
ABI1 in BCR-ABL induced cytoskeletal remodeling, altered adhesion and migration of leukemic 
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cells (Li et al., 2007; Zhuang et al., 2011; Sato et al., 2011; Sun et al., 2008). The Ras effector 
protein RIN1 is another ABL interacting protein that binds to the ABL SH3 domain through its 
PxxP motif and to the ABL SH2 domain via a phosphotyrosine residue (Cao et al., 2008). 
Interaction of RIN1 with ABL removes the autoinhibitory contribution of both SH3 and SH2 
domains and stabilizes the active conformation of ABL. Other interacting partners that are 
implicated in negative regulation of ABL kinase activity include but are not limited to PRDX1 
(PAG) and TUSC2 (FUS1) (Wen and Van Etten, 1997; Lin et al., 2007). 
1.6 CONFORMATIONAL DYNAMICS OF C-ABL PROTEIN 
In collaboration with Professor John Engen at Northeastern University, our laboratory has 
previously studied the conformational dynamics of the ABL regulatory region (Ncap-SH3-SH2-
linker) as well as the intact c-ABL core using Hydrogen Exchange (HX) coupled with Mass 
Spectrometry (MS). This section gives an overview of the principles of the HX MS technique 
and summarizes the findings of these previous studies which form the foundation for my thesis 
project. 
1.6.1 Hydrogen exchange mass spectrometry (HX MS) 
Proteins are dynamic macromolecules in solution that respond to different stimuli and their 
function and regulation cannot be fully understood based solely on a static structural view such 
as that provided by X-Ray crystallography. In this regard, HX MS is used to understand how 
conformational changes and dynamic properties of proteins correlate with structure and function. 
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Hence, HX MS reveals the dynamic aspects of a protein that complement available crystal 
structures (Engen, 2009). 
The fundamental principle of HX MS is the exchange of hydrogen atoms (1.0078 Da) in 
proteins with deuterium atoms (2.0141 Da) upon exposure to D2O solvent followed by detection 
and analysis of this exchange process by MS. The hydrogens that are detected by the exchange 
process are the backbone or amide hydrogens. These amide hydrogens are present in all amino 
acids except for proline and are hydrogen bonded either to other parts of the protein or to water. 
Thus the relative rate of exchange at the backbone is useful in studying conformational changes. 
The hydrogens in the side chains of amino acids are also deuterated during the exchange 
reaction.  However, deuterium is back-exchanged during sample processing and does not 
contribute to the observed increase in mass.  In contrast, hydrogens bonded directly to carbon do 
not undergo exchange (Figure 3 A).  
During HX MS experiments, when temperature and pH are held constant, solvent 
accessibility and hydrogen bonding are the primary factors that affect the rate and location of 
deuterium incorporation. In folded proteins, hydrogens in highly dynamic regions exposed to 
solvent display fast deuteration while regions less exposed to solvent or involved in hydrogen 
bonding display slower exchange kinetics. Hence, when there is a conformational change that 
exposes certain regions of the protein to the solvent or changes local hydrogen bonding, the 
location and extent of deuterium exchange reflecting these changes can be monitored and 
detected over time.  
In general, continuous deuterium labeling is commonly used to label proteins which are 
initially equilibrated in H2O buffer at room temperature and physiological pH.  Deuteration is 
initiated by diluting the protein in the same buffer except that D2O is the solvent instead of H2O. 
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The labeling reaction is then quenched at various time points (seconds to minutes to hours) by 
lowering the pH to 2.5 and the temperature to 0°C. Under these conditions, the rate of the 
exchange reaction is reduced by a factor of ~105, which is critical to limit back-exchange 
(Sebastien Brier and John R.Engen, 2008). Intact proteins are then sprayed into the mass 
spectrometer and monitored for increases in mass due to deuterium incorporation. Studying the 
change in mass of an intact protein over time reveals global changes but does not indicate the 
location of deuterium incorporation. Intact protein exchange may also reveal the presence of 
different populations of molecules that acquire deuterium at different rates.  Such a difference 
may reflect the rate of interconversion between folded and unfolded protein states (more below). 
To have spatial resolution for the deuterium incorporation, proteins can be digested by pepsin 
under quench conditions, separated by chromatography and injected into MS. Subsequent 
detection and analysis of the peptic peptides can reveal the location of the deuterium 
incorporation (Wu and Engen, 2004; Wales and Engen, 2006; Sebastien Brier and John R.Engen, 
2008; Marcsisin and Engen, 2010).  
As discussed above, HX MS is capable of detecting populations of molecules and their 
interconversion between folded and unfolded states over time (Figure 3 B). When the refolding 
rate of a protein is much greater than the deuterium exchange rate, then the protein exhibits EX2 
kinetics. EX2 kinetics is common in proteins and can be detected in the mass spectra as a single 
peak that increases in mass over the course of the labeling time. On the other hand, a rarer event 
in protein dynamics is termed EX1 kinetics. EX1 kinetics is observed when the rate of unfolding 
and refolding is much slower than the deuterium exchange rate.  Proteins undergoing EX1 
exchange exhibit a unique bimodal isotopic distribution in the mass spectra. The bimodal pattern 
is contributed by unfolded species that have higher mass due to more deuterium incorporation 
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than the folded species. Using HX MS, the Engen group discovered EX1 kinetics in the SH3 
domain of Src-family kinase, HCK. The HCK SH3 domain undergoes a slow cooperative 
unfolding-refolding event under physiological conditions with a half-life of ~20 min. Using the 
HCK SH3 unfolding as a reference point, many other SH3 domains were studied and compared 
including the ABL SH3. Interestingly the ABL SH3 domain also exhibited slow cooperative 
unfolding with a half-life of ~10 min. This observation was crucial in establishing a biophysical 
approach to measuring the modification of the SH3 unfolding rate in the presence of SH3-
binding ligands, SH3:linker interaction and in the cases of mutations or modifications in the 
linker or the SH3 domain itself. 
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Figure 3: Overview of amide hydrogen exchange in proteins. A) Amino acid sequence showing amide hydrogens 
(blue). Backbone nitrogen (brown) in proline has no amide hydrogen. Amide hydrogens exchange with solvent 
hydrogens when exposed and become deuterated (red) when placed in a solution of D2O. The exposed and dynamic 
regions of proteins will exchange more rapidly than protected regions as shown in the lower part of figure A. B) The 
equation showing the rate constants for unfolding (K1) and refolding (K-1) of proteins in solution. The lower panel 
shows EX1 and EX2 kinetics with their respective mass spectra. EX1 exchange occurs when the unfolding rate is 
faster than the refolding rate, resulting in two populations of molecules, one deuterated (higher mass peak) and the 
other not deuterated (lower mass peak). EX2 occurs when refolding rate is much faster than unfolding rate resulting 
in single population of molecules that increase in mass upon deuteration over time. Adapted from (Marcsisin and 
Engen, 2010; Weis et al., 2006). 
 
The dynamic association between the ABL SH3 domain and the SH2-kinase linker was 
studied by monitoring the changes in cooperative unfolding of ABL SH3 domain. In this study, 
the unfolding of the SH3 domain upon association with the linker was determined in a series of 
recombinant ABL SH3-SH2-linker proteins that lacked the kinase domain. To define the linker 
residues necessary for the association, the constructs included different lengths of the linker. 
Comparison of the rate of SH3 domain unfolding in SH3-SH2 proteins with and without the 
linker showed that the presence of the linker slowed down the unfolding rate, providing direct 
evidence for SH3:linker interaction. However, a shortened version of the linker that lacked the 
last two residues (Trp254 and Glu255) restored the SH3 unfolding rate to that observed in the 
absence of the linker. This experiment defined the minimum length of the linker required for 
SH3 engagement (Chen et al., 2007).  
Furthermore, studies using HX MS investigated the contribution of the NCap in 
stabilizing the intramolecular interactions with different constructs of ABL (SH3/3, SH3-
SH2/32, SH3-SH2-Linker/32L) (Chen et al., 2008a). In this study, changes in the partial 
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unfolding half-life of SH3 domain in the presence or absence of the other domains were 
measured.  The results showed that the NCap stabilizes SH3 unfolding in the presence of the 
SH2 domain but not in its absence. Also, the SH3 unfolding half-life was doubled in NCap32L 
relative to the 32L protein. This study clearly shows that NCap contributes to SH3 stabilization, 
and that this influence requires the SH2 domain. In doing so, the NCap may compensate to some 
extent to the absence of the negative regulatory C-terminal tail, which engages the SH2 domain 
in the downregulated conformation of c-SRC and other SFKs. This study also suggests that 
fusion of BCR to ABL, which removes the stabilizing effect of NCap, contributes to kinase 
activation (Chen et al., 2008a). 
Prior work from our laboratory showed that Src family kinases phosphorylate the ABL 
SH3 domain at Tyr89. Phosphorylation at this site enhances kinase activity and is required for 
the full transforming activity of BCR-ABL protein. In the crystal structure of the downregulated 
c-ABL core, Tyr89 is at the interface between the SH3 domain and the SH2-kinase linker. HX 
MS studies demonstrated that phosphorylation of Tyr89 by the SFK HCK disengages SH3 from 
the linker, disrupting its negative regulatory interaction with the linker. This result is consistent 
with the biological data, in which phosphorylation of this site is required for full kinase activity. 
Phosphorylation at this residue also interferes with the binding of the ABL interacting protein 
ABI1 to the SH3 domain (Chen et al., 2008b; Meyn, III et al., 2006). 
HX MS was also used to investigate conformational changes in the complete c-ABL 
kinase core (NCap-SH3-SH2-kinase). These studies addressed conformational changes resulting 
from imatinib resistance mutations as well as binding of allosteric inhibitors to the myristic acid 
binding site either alone or in combination with ATP competitive inhibitors. The most 
recalcitrant imatinib resistant mutation is the T315I mutation also known as the ‘gatekeeper’ 
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mutation. This substitution not only results in the loss of hydrogen bonding with the drug and a 
steric clash in the drug binding pocket, but it also activates the kinase (discussed in more detail in 
Section 1.9.3.2) (Shah et al., 2002; Azam et al., 2008). Remarkably, the ABL T315I protein 
showed increased deuterium incorporation not only at the site of the mutation reflecting local 
conformational changes but also at a distant site in the SH3 domain (Iacob et al., 2011). 
Subsequent studies showed that binding of allosteric inhibitor GNF-5 to the myristic acid 
binding pocket induces both local dynamic changes as well as allosteric changes in the ATP-
binding site. These observations have important implications for the mechanisms of drug 
resistance (addressed in Section 1.11, below). Indeed, simultaneous binding of GNF-5 and the 
ATP-competitive inhibitor to ABL T315I induced similar conformational changes to those 
observed when dasatinib was bound to wild-type ABL (Iacob et al., 2011; Zhang et al., 2010). 
This observation supports the idea that binding of small molecule antagonists to the myristate 
binding pocket helps to stabilize the downregulated conformation of the active site, thus 
promoting synergy with dasatinib. 
1.7 BCR-ABL 
The causal relationship between expression of BCR-ABL and CML pathogenesis is well 
established. Fusion of BCR to ABL and consequent activation of the ABL kinase is essential for 
BCR-ABL oncogenicity. Expression of BCR-ABL in mouse fibroblasts, human CD34+ myeloid 
progenitor cells, and primary bone marrow cells all lead to increased cell proliferation, factor-
independent growth and survival, as well as reduced adhesion to fibronectin (Ren, 2005; 
Ramaraj et al., 2004; Zhao et al., 2001; Ren, 2002). These properties mimic those of transformed 
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hematopoietic progenitor cells isolated from CML patients. Besides transformation of cells in 
culture, retroviral transduction of mouse bone marrow cells with BCR-ABL induces 
myeloproliferative disease (MPD) that resembles CML following transplantation into irradiated 
mice (Daley et al., 1990). Furthermore, expression of kinase-dead forms of BCR-ABL in the 
bone marrow transplantation mouse model of CML does not induce leukemogenesis, providing 
direct evidence that kinase activity is critical to the evolution of the disease in vivo (Ren, 2005). 
As described in Sections 1.0 and 1.1, BCR-ABL is the chimeric oncoprotein that drives 
CML pathogenesis.  BCR fusion removes most of the NCap from the N-terminus of c-ABL 
removing important negative regulatory elements from the tyrosine kinase portion of the protein. 
In addition, fusion of BCR adds structural features crucial to the activation of downstream 
signaling pathways and oncogenic activities of BCR-ABL. BCR has a coiled-coil 
oligomerization domain at the N-terminus (McWhirter et al., 1993; Zhao et al., 2002), and fusion 
of BCR to ABL induces clustering and juxtaposition of kinase domains that leads to 
intermolecular trans-phosphorylation and activation of the kinase. The coiled-coil domain is 
followed by serine/threonine kinase domain, a Dbl/CDC24 guanine-nucleotide exchange factor 
homology domain (DH), a pleckstrin homology domain (PH), calcium-dependent lipid binding 
site (CaLB), a RAC guanosine triphosphatase-activating protein (RAC-GAP) domain, a growth 
factor receptor-bound protein 2 (GRB2) docking site as well as binding sites for GRB10, 14-3-3 
and an ABL SH2 binding domain (Advani and Pendergast, 2002; Quintas-Cardama and Cortes, 
2009). 
BCR-ABL drives CML through its interaction with many signaling proteins and 
induction of downstream signaling pathways. These pathways can be mechanistically grouped as 
follows: 1) altered adhesion to stroma cells and extracellular matrix, 2) mitogenic signaling 
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pathways, 3) reduced apoptosis, and 4) increased proteasomal degradation of negative regulators 
(Deininger et al., 2000).  Examples of these pathways are provided in the following sections. 
1.7.1 RAS and MAP kinase pathways  
The mitogen-activated protein kinase pathway (RAS/RAF/MEK/ERK) plays important 
mitogenic and antiapoptotic signaling roles for BCR-ABL via downstream transcription factors 
(Steelman et al., 2008; Steelman et al., 2004). Tyr177 in the BCR portion of BCR-ABL is an 
important residue for interaction with adaptor proteins and activation of downstream signaling 
pathways including the MAPK pathway. Upon phosphorylation of this residue, the GRB2 
adaptor protein is recruited and docks onto BCR-ABL. GRB2 in turn recruits the guanine 
nucleotide exchange factor, SOS (named for the orthologous Drosophila protein, Son of 
Sevenless) which activates Ras. Binding of GRB2 also promotes docking of GAB2 which in turn 
activates the PI3K/AKT pathway as discussed in Section 1.7.3. Mutation of Tyr177 to 
phenylalanine abolishes binding of GRB2 and activation of Ras. As a consequence, the 
transformation of primary bone marrow cultures by this mutant is also impaired and the 
induction of MPD in vivo is reduced (Pendergast et al., 1993; Ren, 2005). On the other hand, 
BCR-ABL-mediated Ras activation has also been shown to occur through two other adaptor 
proteins, SHC and CRKL (Oda et al., 1994; Puil et al., 1994). Independent studies showed that 
docking of SHC requires BCR-ABL SH2 domain as well as its kinase activity. Following its 
tyrosine phosphorylation, SHC can recruit GRB2 and activate RAS. CRKL is highly expressed 
in hematopoietic cells and binds to BCR-ABL through its N-terminal SH3 domain (de et al., 
1995; ten et al., 1994). CRKL was also shown to bind to C3G, another guanine nucleotide 
exchange factor (Feller et al., 1998). Hence, BCR-ABL can also activate the Ras pathway by 
 27 
binding and phosphorylating the CRKL-C3G complex (Goga et al., 1995b; Cortez et al., 1995; 
Cortez et al., 1996).  
1.7.2 JAK/STAT pathway 
The Janus (JAK) family of non-receptor tyrosine kinases is composed of four members (JAK1, 
JAK2, JAK3 and Tyk2). Jaks are rapidly activated by many cytokines and growth factors and 
couple receptor activation to effector recruitment downstream.  Important effectors in this 
pathway include the signal transducer and activator of transcription (STAT) factors, which are 
recruited to the receptor via their SH2 domains followed by JAK-mediated phosphorylation. 
Following phosphorylation and dimerization, STATs are transported into the nucleus, bind to 
DNA and transcribe genes responsible for cell growth, survival and differentiation. Several 
STAT transcription factors are constitutively activated by BCR-ABL in CML cells, including 
STAT1, STAT3 and STAT5, with STAT5 being the most prominent. STAT5 plays a major role 
in leukemia initiation, maintenance, progression as well as imatinib resistance. STAT5 activation 
leads to increased expression of the anti-apoptotic proteins Mcl-1 and Bcl-XL as well as Cyclin 
D1 which is essential to the progression from G1 to S phase of the cell cycle (Ilaria, Jr. and Van 
Etten, 1996; Carlesso et al., 1996; Frank and Varticovski, 1996; Gesbert and Griffin, 2000; 
Sillaber et al., 2000; de Groot et al., 2000).  The mechanism of STAT activation by BCR-ABL is 
complex, involving both direct phosphorylation as well as intermediate kinases of the SRC and 
JAK families as described in the following sections. 
JAK2 is an important non-receptor kinase that is activated by point mutations in many 
myeloproliferative diseases. JAK2 has also been associated with BCR-ABL mediated 
leukemogenesis, as pharmacological inhibition of JAK2 decreases the viability of both imatinib-
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sensitive and resistant CML cells. However a more recent report shows that inhibition of JAK2 
was correlated with “off-target” effects of JAK2 inhibitors such as TG101348, TG101209 and 
AG490 on BCR-ABL directly (Hantschel et al., 2012). Samanta et al. showed that activation of 
JAK2 by BCR-ABL induces phosphorylation of GAB2, thus linking JAK2 to the 
phosphatidylinositol-3-kinase (PI3K) and Ras pathways (Samanta et al., 2006; Samanta et al., 
2011). Although BCR-ABL phosphorylates JAK2 on Tyr1007, cells expressing kinase-inactive 
JAK2 do not exhibit reduced levels of active STAT5 (Xie et al., 2001). More recently, Hantschel 
et al showed that STAT5 activation is uncoupled from JAK2 activation in BCR-ABL expressing 
cells and that STAT5 is directly phosphorylated by BCR-ABL (Hantschel et al., 2012). 
1.7.3 Phosphatidylinositol 3-kinase (PI3K) Pathway 
PI3Ks are a family of kinases that phosphorylate membrane phosphatidylinositols on the 3’-
hydroxyl inositol head group. PI3K lipid products create docking sites for proteins with 
pleckstrin homology domains such as the kinases Akt and phosphoinositide-dependent kinase-1 
(PDK-1). PI3Ks of class IA are activated downstream of tyrosine kinases and are composed of 
regulatory and catalytic subunits.  Class IA PI3Ks are heterodimers consisting of a catalytic 
subunit of 110kDa (p110α, p110β and p110δ) and a regulatory subunit (p85α, p85β and p55γ). 
Phosphatidylinositol-3,4,5-triphosphate (PIP3) accumulates in BCR-ABL transformed 
cells, and pharmacological inhibition of PI3K blocks myeloid and lymphoid transformation 
indicating functional relevance and activation of PI3K downstream of this oncogene (Skorski et 
al., 1997; Kharas et al., 2004). The mechanism of PI3K activation downstream of BCR-ABL has 
been controversial. Jain’s et al. showed that mutation of the ABL domain that interacts with p85 
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subunit of PI3K did not abrogate PI3K activity (Jain et al., 1996). This study suggested that pI3K 
can be activated by other proteins that are tyrosine phosphorylated by BCR-ABL.  
One crucial pathway for activation of PI3K involves BCR-ABL Tyr177. As described in 
the preceding section, phosphorylation of this BCR residue recruits GRB2 and hence GAB2 
adaptor proteins. GAB2 is then tyrosine-phosphorylated and the p85 regulatory subunit docks 
onto GAB2 by virtue of its SH2 domain, followed by activation of the PI3K catalytic subunit 
(Sattler et al., 2002). Mutation of Tyr177 to phenylalanine abolishes GAB2 association, 
decreases GAB2 phosphorylation and PI3K activation. Furthermore, murine myeloid cells from 
GAB2-null mice could not be transformed by BCR-ABL. These experiments suggest that 
Tyr177 and GAB2 are required for BCR-ABL-mediated activation of PI3K. PI3K is also 
activated by BCR-ABL through a GAB2-independent mechanism that involves the adaptor 
proteins CRKL, c-CBL and c-CRK. CRKL or c-CRK associate with ABL through their 
respective SH3 domains and to c-CBL through their SH2 domains. PI3K is then recruited to 
phospho-CBL through its p85 regulatory subunit and is activated (Sattler et al., 1996). 
One major downstream effector of PI3K is the Ser/Thr kinase, AKT, which plays an 
important role in regulating growth and survival associated with BCR-ABL-mediated 
transformation. There are several AKT substrates that provide a survival advantage to BCR-
ABL-transformed cells and contribute to transformation, including the Forkhead Box Subgroup 
O (FOXO) transcription factors. AKT-mediated phosphorylation of FOXO transcription factors 
sequesters them in the cytoplasm through their association with 14-3-3 chaperones. As a result, 
transcription of proapoptotic proteins are reduced (Obsilova et al., 2005). Proapoptotic BAD is 
also phosphorylated by AKT and sequestered by 14-3-3. Unphosphorylated BAD associates with 
the anti-apoptotic BCL-2 protein, displacing BAX which is then available for mitochondrial 
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permeabilization and apoptosis via cytochrome C release. However, AKT-dependent 
phosphorylation of BAD and 14-3-3 binding prevents its association with BCL-2 which 
sequesters BAX, thus inhibiting BAX associated apoptosis (Zha et al., 1996). Another target of 
AKT is glycogen synthase kinase-β (GSK3β) which is inactivated by phosphorylation. When it 
is inactivated, GSK3β cannot phosphorylate its downstream targets such as β-Catenin and Cyclin 
D1 that otherwise would be targeted for proteasomal degradation. As a result β-Catenin 
accumulates in the nucleus and drives the transcription of target genes such as c-MYC and c-
JUN which contribute to cell survival (Pap and Cooper, 1998; Diehl et al., 1998). β-Catenin also 
interacts with BCR-ABL directly leading to its stability in a GSK3β- independent way (Coluccia 
et al., 2007).  
1.7.4 BCR-ABL signaling through Src-Family Kinases 
Src-family kinases (SFKs) play a central role in BCR-ABL signaling in CML and there is 
accumulating evidence for their role in imatinib resistance as well.  These observations have led 
to the development of drugs that target the kinase activities of both BCR-ABL and SFKs, such as 
dasatinib (Martinelli et al., 2005; Kantarjian et al., 2011). 
Initial evidence for SFK activation came from studies in murine 32D cells transformed 
with BCR-ABL and in the human K562 CML cell line (Danhauser-Riedl et al., 1996). In these 
cells, BCR-ABL associates with and activates the myeloid SFKs, HCK and LYN. The 
association of HCK and BCR-ABL involves the SH3, SH2, kinase and C-terminal regions of 
BCR-ABL and the SH3 and SH2 domains of HCK. Interestingly, this association did not require 
the kinase activity of ABL (Stanglmaier et al., 2003a; Lionberger et al., 2000; Warmuth et al., 
1997).   
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SFKs also act as mediators of signaling pathways downstream of BCR-ABL. For 
example, Stat5 activation is mediated by HCK in myeloid cells as expression of kinase-dead 
HCK attenuates phosphorylation of Stat5 at Tyr699 and abolishes BCR-ABL induced 
transformation of myeloid cells (Klejman et al., 2002). Further evidence to support a role for 
SFKs in BCR-ABL mediated signaling comes from pharmacological inhibition of these kinases. 
Previous work from our laboratory showed that selective inhibition of SFKs in CML cell lines by 
the pyrrolopyrimidine A-419259, an SFK-selective inhibitor, blocks cell proliferation and 
induces apoptosis only in BCR-ABL expressing cells. Indeed, the specific inhibition of SFK 
activity with this compound correlated with downregulation of STAT5 and ERK activity 
(Lionberger et al., 2000; Wilson et al., 2002).  More recently, our group has shown that A-
419259 also induces apoptosis in primary CD34+ cells from CML patients with similar potency 
to imatinib (Pene-Dumitrescu et al., 2008). 
SFKs have also been implicated in the regulation of both c-ABL and BCR-ABL through 
direct phosphorylation of key tyrosine residues involved in kinase regulation and signaling. Both 
LYN and HCK have been implicated in phosphorylation of Tyr177 in the BCR-derived portion 
of BCR-ABL (Warmuth et al., 1997; Meyn, III et al., 2006; Wu et al., 2008). The 
phosphorylation of this residue is important as a docking site for GRB2 and other adaptor 
proteins and activation of downstream signaling pathways as discussed earlier. Phosphorylation 
of Tyr412 in the c-ABL activation loop is mediated by SFKs in response to growth factor 
stimulation. Tyr245 in the SH2-kinase linker is also phosphorylated by SFKs, which results in 
upregulation of c-ABL activity. In addition, work from our laboratory has shown that FYN, LYN 
and HCK strongly phosphorylate multiple tyrosine residues in BCR-ABL SH3-SH2 region. 
These phosphorylation sites were identified by mass spectrometry and include: Tyr89 and 
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Tyr134 (SH3 domain), Tyr147 (SH3-SH2 connector), Tyr158, Tyr191, Tyr204 and Tyr234 (SH2 
domain). Substitution of these residues with phenylalanine reduced the transforming potential of 
BCR-ABL in the human myeloid leukemia cell line, TF-1. Based on their positions in the 
downregulated conformation of the c-ABL core, phosphorylation of these sites may have an 
important role in regulating the intramolecular interactions, kinase activity and might interfere 
with drug binding and sensitivity (Meyn, III et al., 2006). As discussed in Section 1.6.1, 
phosphorylation of SH3 Tyr89 causes displacement of SH3 from the linker, providing direct 
biophysical evidence for this idea. 
1.8 CML THERAPY BEFORE IMATINIB 
CML therapy in the early 1900s was purely palliative and included splenic irradiation and the 
use of cytostatic agents such as busulfan and hydroxyurea. Over time, the goal of CML treatment 
became curative with the introduction of allogeneic stem cell transplantation. The requirements 
for successful transplant are many and include patient tolerance of the aggressive chemotherapy 
and irradiation used to kill the leukemic cells prior to transplantation, age of the patient (older 
patients have more complications), the stage of the disease and most importantly availability of a 
compatible donor (Hehlmann et al., 2007; Hehlmann et al., 2005).  
In cases where allogeneic stem cell transplantation is not possible, or in cases of relapse 
following transplantation, interferon alpha (IFN-α) in combination with hydroxyurea or cytosine 
arabinoside (Ara-C) was a standard treatment. IFN-α leads to hematologic and cytogenetic 
responses in the chronic phase of CML. However, over time the majority of patients have 
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reduced quality of life due to the adverse effects of IFN-α and also develop resistance (Hehlmann 
et al., 2007).  
1.9 IMATINIB: TARGETED FRONT LINE THERAPY FOR CML 
The first evidence that a tyrosine kinase could be targeted by pharmacological inhibitors came in 
1988 when Yaish’s group described compounds called tyrphostins that inhibit the epidermal 
growth factor receptor (EGFR) (Yaish et al., 1988). At the same time, screening of compound 
libraries at Novartis (Ciba-Geigy at the time) identified 2-phenylaminopyrimidine compounds as 
promising tyrosine kinase inhibitors, although the original compounds had low specificity and 
potency (Buchdunger et al., 1995). Imatinib was later developed as an inhibitor of this chemical 
class with specificity for the PDGFR, and was subsequently shown to inhibit ABL tyrosine 
kinases and stem-cell factor receptor c-KIT. A landmark 1996 paper from the Druker laboratory 
reported that imatinib inhibited myeloid cells expressing BCR-ABL but not cells that are BCR-
ABL negative (Druker et al., 1996). In addition, imatinib inhibited colony formation of cells 
from CML patients (Druker et al., 1996; Savage and Antman, 2002a). Following these in vitro 
studies, oral administration of imatinib to mice bearing human-derived CML cells inhibited 
tumor growth with minimal side effects (Buchdunger et al., 1996; le et al., 1999). Based on these 
promising preclinical data, clinical trials with imatinib began in 1998. In phase I clinical trials, 
the efficacy and safety of imatinib was investigated in chronic phase CML patients. In this study, 
imatinib showed remarkable success whereby 98% of patients displayed a complete hematologic 
response (CHR) and this response was maintained over a year.  Fifty-five percent of the patients 
in the accelerated or blast crisis phase achieved partial hematological responses. In phase II 
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clinical trials, despite great responses of patients in the chronic phase, patients in the accelerated 
and blast crisis phases achieved 69% and 29% CHR rate respectively. The Phase III study was 
the International Randomized Study of Interferon and STI571 (IRIS). This study compared 
imatinib at 400 mg/dl with the standard treatment at the time (IFN-α plus Ara-C) in over 1000 
patients. Compared to patients on INFα and Ara-C, the imatinib treatment group showed a 
significantly higher complete cytogenetic response rate (CCyR) and event-free survival after 60 
months. However, after 8 year follow up from the study 17% of patients did not achieve 
complete cytogenetic response, 15% lost their response and 5% could not tolerate imatinib. 
Given the overall efficacy and survival rate, imatinib was approved by the FDA in 2001 for the 
treatment of CML disease (Savage and Antman, 2002b; Fava et al., 2012) and is now the first-
line therapy for CML. 
1.9.1 Imatinib: Mechanism of action 
Imatinib is 2-phenylaminopyrimidine ATP-competitive inhibitor that has high affinity and 
specificity for ABL tyrosine kinases.  Structural studies of the ABL kinase domain by the 
Kuriyan group showed that imatinib binds between the N- and C-lobes of the kinase domain near 
the activation loop and the helix αC. Interestingly, imatinib preferentially binds to the 
downregulated structure of the kinase. In the downregulated state the salt bridge between Glu286 
of helix αC and Lys271 of the N-lobe is maintained but the highly conserved DFG motif is 
flipped out, inhibiting ligation of a critical magnesium ion by the conserved aspartate residue 
(discussed earlier in Section 1.4.5). The outward rotation of the DFG motif also results in the 
movement of the flexible activation loop such that the tyrosine autophosphorylation site forms a 
hydrogen bond with the catalytic aspartate, mimicking the effect of bound substrate. The binding 
 35 
of imatinib is stabilized by 21 interactions, of which 6 are hydrogen bonds with Met318, Thr315 
(the gatekeeper residue mentioned earlier), Glu286, His361, Ile360 and Asp381 (Schindler et al., 
2000). The specificity of imatinib binding to ABL is achieved by the conformational structure of 
ABL in its inactive form which is unique even when compared to the highly similar structures of 
SFKs. Thus, although these kinases have similar structures in their active states, differences in 
the inactive states can be exploited to achieve differential inhibition by imatinib (Levinson et al., 
2006b; Nagar, 2007; Nagar et al., 2002).  
1.9.2 Imatinib Resistance 
Despite the unprecedented hematologic and cytogenetic response rates with imatinib, resistance 
to imatinib treatment is a growing concern. It is estimated that about 20-30% of CML patients 
will eventually develop resistance to imatinib (Quintas-Cardama and Cortes, 2009).  Resistance 
to imatinib can be divided into two categories: primary resistance and acquired resistance. 
Acquired resistance can be further subdivided into BCR-ABL dependent or independent 
mechanisms. Each of these types of resistance is discussed in more detail below. 
Primary resistance is a rare event. Patients who fail to achieve complete hematologic 
response after 3 months from the start of imatinib therapy, cytogenetic response by 6 months, 
partial cytogenetic response by 12 months or complete cytogenetic response by 18 months are 
considered to be insensitive to imatinib. The mechanisms driving primary resistance are not very 
well understood. However, one possible explanation for primary resistance is the presence and 
refractoriness of CML stem cells (Graham et al., 2002; Holtz et al., 2005; Holtz et al., 2002). 
These quiescent cells are intrinsically resistant to imatinib therapy. The insensitivity of these 
quiescent cells may include alterations in drug uptake, efflux, expression level of BCR-ABL 
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transcript, increased activity level and kinase domain mutations that occur even prior to imatinib 
therapy (Ernst et al., 2008; Copland et al., 2006) . 
In acquired resistance, patients initially respond to imatinib for various periods of time 
but eventually become drug resistant. This type of drug resistance is characterized at three levels: 
hematologic, cytogenetic and molecular. Thus in acquired resistance, patients lose their 
hematologic response and hence cannot normalize their peripheral blood counts, Ph chromosome 
positive cells persist, and at the molecular level BCR-ABL transcripts are still present (Quintas-
Cardama et al., 2009; Roychowdhury and Talpaz, 2011). 
1.9.3 BCR-ABL-dependent mechanisms of acquired imatinib resistance 
1.9.3.1 BCR-ABL overexpression  
BCR-ABL gene amplification results in overexpression of the protein. BCR-ABL gene 
amplification was first observed in studies using BCR-ABL-transformed Ba/F3 cells (Mahon et 
al., 2000). Clinically, the first studies on the 11 patients who presented with imatinib resistance, 
3 patients showed gene amplification when studied by fluorescent in situ hybridization (FISH) in 
the absence of kinase domain mutations (Gorre et al., 2001). However, when a larger group of 
patients were tested for BCR-ABL gene amplification, 2 of 66 patients were positive for the 
amplification (Gorre et al., 2001; Hochhaus et al., 2002). Interestingly, a correlation has been 
reported between high levels of BCR-ABL protein and a faster rate of imatinib resistance 
mutations (Barnes et al., 2005). 
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1.9.3.2 Kinase Domain Point mutations 
The first report of ABL kinase domain mutations associated with imatinib resistance was 
reported by Gorre and coworkers. This study reported a single nucleotide change that resulted in 
threonine to isoleucine substitution at position 315 of the kinase domain (Gorre et al., 2001). 
This mutation is the most recalcitrant mutation known to date and is unresponsive to all 
clinically available drugs. When this mutation was identified, the crystal structure of ABL kinase 
domain bound with a variant of imatinib had just been solved (Schindler et al., 2000). Modeling 
the T315I mutation on this structure (Nagar et al., 2002), it was evident that isoleucine could not 
form a critical hydrogen bond with the secondary amino group of imatinib and also the bulkier 
isoleucine side chain would sterically hinder the binding of imatinib to the drug-binding pocket. 
Furthermore, Daley’s group showed that mutations at the gatekeeper residue in the c-ABL, c-
SRC, PDGFR and EGFR activate the kinases (Azam et al., 2008). In the same study, structural 
analysis, mutagenesis and cell based assays showed that in ABL the gatekeeper mutation 
stabilizes the hydrophobic spine which was first defined by Kornev’s group (Kornev et al., 
2006). The four residues that make up the hydrophobic spine, Leu320, Met309, Phe401 and 
His380, are ordered in the active state of the kinase and threonine to isoleucine substitution that 
would occur at the tip of the spine that stabilizes the active conformation of the kinase. In 
addition, work from our group showed that T315I induces dynamic conformational changes 
locally at the site of the mutation as well as in the SH3 domain of myristoylated ABL core 
protein (Iacob et al., 2009).  Taken together, these studies show that T315I substitution has 
important implications not only for imatinib resistance for loss of kinase regulation as well. 
Following the first report of T315I mutation in a small group of patients (Gorre et al., 
2001), studies of BCR-ABL kinase domain mutations in a larger cohort group of patients with 
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imatinib resistance revealed that 29 of the 32 patients had kinase domain mutations (Shah et al., 
2002). The mutations involved 15 amino acid substitutions at 13 distinct kinase domain 
positions, involving the P-loop, the catalytic loop as well as the activation loop. While some of 
these residues are directly involved in imatinib binding, others do not contact imatinib directly 
but instead have an effect on the conformation of the kinase that prevents its interaction with 
imatinib. A comprehensive study using random mutagenesis of BCR-ABL to study the different 
amino acid substitutions conferring resistance to imatinib was reported by Azam et al (Azam et 
al., 2003).  This approach identified all of the mutations previously observed in clinical samples 
and numerous others. Clinically relevant mutations were distributed along the whole kinase 
domain, and include the P-loop, the activation loop, helix αC, the SH2 and SH3 domains, the 
SH3-SH2 connector as well as the SH2-kinase linker (the positions of these residues are mapped 
to the structure of the ABL core in Figure 4). The numerous mutations recovered that did not 
directly interfere with imatinib binding defined a new class of mutations that can confer 
resistance by allosteric modification of the downregulated structure of the kinase. Despite the 
large number of resistance mutations that have been reported so far, most of these are rare in 
terms of clinical experience, with changes at ABL residues Gly250, Tyr253, Glu255, Thr315, 
Met351 and Phe359 accounting for about 60-70% of kinase domain point mutations (Quintas-
Cardama et al., 2009). 
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Figure 4: Point mutations leading to imatinib resistance in BCR-ABL. Residues that render BCR-ABL resistant 
to imatinib are mapped on the downregulated structure of ABL core (PDB:F2O0). These mutations have been 
identified in an unbiased in vitro screen (Azam et al., 2003). The NCap region is rendered in pale cyan; SH3 domain 
in red; SH3-SH2 connector in grey; SH2 domain in green; SH2-kinase linker in orange; kinase domain in light blue. 
These residues are numbered as per the crystal structure (ABL1b residues 1-531, 15-56 deleted), and are offset 
relative to the numbering convention used for BCR-ABL residues.  Thus the gatekeeper residue is numbered as 
T334 rather than T315 in this scheme. 
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1.9.4 BCR-ABL-independent mechanisms of resistance 
Kinase domain mutations and gene amplification account for about 50% of resistant cases in 
CML(Roychowdhury and Talpaz, 2011). Thus, BCR-ABL-independent mechanisms also 
contribute to clinical imatinib resistance in CML and include α-1 acid glycoprotein levels, drug 
transport, metabolism by cytochrome p450, BCR-ABL downstream signaling and minimal 
residual disease. 
Plasma levels of imatinib have been correlated with α-1 acid glycoprotein levels (AGP), 
which increase in the advanced stages of CML. Binding of imatinib to AGP has been shown to 
increase the clearance of imatinib in patients with gastrointestinal stromal tumors treated with 
imatinib (le et al., 2002; Gambacorti-Passerini et al., 2002; Delbaldo et al., 2006). 
Intracellular levels of imatinib are a function of influx and efflux of the drug. Imatinib is 
a substrate of the ATP-binding cassette transporter ABCB1 that has been shown to be 
overexpressed in patient samples in the advanced stages of CML and many other cancers (Dai et 
al., 2003; Thomas et al., 2004). The overexpression of this transporter increases the efflux of 
imatinib and potentially contributes to drug resistance. However, the role of ABCB1 transporter 
in inducing imatinib resistance remains controversial as the activity of this transporter on 
imatinib relative to other cytotoxic agents is very small and the overexpression of ABCB1 in the 
K562 CML cell line does not lead to imatinib resistance in vitro (Ferrao et al., 2003). On the 
other hand, imatinib is transported into the cell through the human organic cation transporter 
(hOCT1). Low levels of hOCT1 have been associated with suboptimal responses in patients 
while higher activity levels have been associated with an improved response rate (Crossman et 
al., 2005). Along with drug transport and association with AGP, levels of the cytochrome p450 
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isoenzymes CYP3A4 and CYP3A5 that metabolize imatinib are important contributors to plasma 
levels and thus its effectiveness (Quintas-Cardama et al., 2009). 
Alterations of signaling pathways downstream of BCR-ABL can also contribute to 
imatinib resistance. Signaling through SFKs has attracted major attention in the context of 
imatinib resistance and hence drug development.  Early experiments showed that K562 CML 
cells made resistant to imatinib by culturing in increasing concentrations of the drug displayed 
upregulation of LYN kinase activity. LYN is a member of the Src-kinase family that is strongly 
expressed in cells of myeloid and B-lymphoid lineage.  Inhibition of LYN kinase by siRNA 
reduced proliferation of these resistant cells in response to imatinib (Ptasznik et al., 2004). 
Furthermore, in samples from patients with advanced CML, imatinib resistance was associated 
with upregualtion of HCK or LYN and reduction of LYN by siRNA reduced cell survival. In 
addition, Chandra’s group showed that FYN levels are upregulated in blast phase of the disease 
compared to the chronic phase (Ban et al., 2008). Also, knockdown of FYN by shRNA slowed 
cell survival and resensitized cells to the effects of imatinib (Gao et al., 2009). The Auberger 
group investigated gene expression profiles of imatinib-resistant as well as pan-Src kinase 
inhibitor-resistant cell lines. In this study they showed increased expression of FYN and its 
inhibition resensitized cells to imatinib (Grosso et al., 2009).  
As discussed earlier, work from our laboratory has shown that FYN, LYN and HCK 
strongly phosphorylate multiple tyrosine residues in BCR-ABL SH3-SH2 region. Substitution of 
these residues with phenylalanine reduced BCR-ABL oncogenicity. Also, the position of these 
residues may have an important role in regulating the intramolecular interactions, kinase activity 
and therefore might interfere with imatinib binding and sensitivity (Meyn, III et al., 2006). In 
support of this notion, it was shown that there are some mutations that occur at the SH3, SH2 and 
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the linker regions in CML patients with different responses to imatinib that may explain clinical 
resistance without kinase domain mutations (Sherbenou et al., 2010). 
Recently, work from our laboratory showed that overexpression of the SFK HCK, as well 
as a gatekeeper mutant of this kinase (HCK T338A) that is specifically inhibited by the 
pyrazolopyrimidine NaPP1, induced imatinib resistance in K562 CML cell lines. The imatinib 
resistance due to overexpression of either form of HCK correlated with sustained BCR-ABL 
tyrosine phosphorylation. Remarkably, NaPP1 treatment reversed the imatinib resistance only in 
cells that expressed HCK T338A but not the control cells expressing wild-type HCK. 
Importantly, HCK-mediated imatinib resistance correlated with specific phosphorylation of 
BCR-ABL on its SH3 domain (Tyr89) and activation loop (Tyr412), and these phosphorylation 
events were reversed by NaPP1 treatment in cells expressing HCK-T338A. These results support 
the idea that HCK kinase activity is sufficient to cause imatinib resistance in the absence of 
BCR-ABL mutations. Resistance may result from HCK-mediated phosphorylation of regulatory 
regions of BCR-ABL that promote active kinase conformations incompatible with imatinib 
binding.  This study also provides a mechanistic basis for SFKs in imatinib resistance and 
provides a rationale for using dual ABL/SRC inhibitors in some cases of imatinib-resistant CML 
(Pene-Dumitrescu et al., 2008; Pene-Dumitrescu and Smithgall, 2010). 
1.10 SECOND GENERATION TYROSINE KINASE INHIBITORS 
Despite the clinical success of imatinib in CML therapy, relapse due to drug resistance is 
inevitable. The emergence of resistance to imatinib through BCR-ABL-dependent mechanisms 
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such as kinase domain mutations, spurred the development of more potent, second generation 
tyrosine kinase inhibitors (TKIs).  
One such second generation TKI is nilotinib (Tasigna, AMN107; Novartis). Nilotinib, 
like imatinib, recognizes and binds the inactive (DFG out) conformation of the kinase. Nilotinib 
is about 30-fold more potent than imatinib as an ABL inhibitor and inhibits c-Kit and the 
PDGFR with similar potency as imatinib (Weisberg et al., 2005). Most importantly, nilotinib 
inhibits 32 of the 33 imatinib-resistant mutants of BCR-ABL both in vitro and in vivo (Weisberg 
et al., 2006; O'Hare et al., 2005). The sole mutant that is unresponsive to nilotinib is the T315I 
‘gatekeeper’ mutation described above. In 2007, the FDA approved nilotinib for the treatment of 
patients resistant to imatinib in the chronic and accelerated phases of the disease (Weisberg et al., 
2007). 
Another second generation tyrosine kinase inhibitor is dasatinib (Sprycel; Bristol-Meyers 
Squibb). Unlike imatinib and nilotinib, dasatinib inhibits both the active and inactive 
conformations of the kinase domain and has a much broader specificity profile, with activity 
against SFKs, c-KIT, PDGFR, ABL and many others (Melnick et al., 2006). Dasatinib is 300 
times more active than imatinib against BCR-ABL and overcomes most imatinib resistant 
mutations with the exception of T315I. In 2006, FDA approved dasatinib for the treatment of all 
phases of CML with resistance to imatinib (Lombardo et al., 2004; Shah et al., 2004; Quintas-
Cardama et al., 2007). 
Bosutinib (SKI-606; Wyeth) is an orally available TKI that has dual SFK and ABL 
tyrosine kinase inhibitory activity. Unlike the other TKIs, bosutinib has no significant activity 
against c-KIT and PDGFR.  This compound also decreases the phosphorylation of many 
downstream cellular proteins including MAPKs, STAT5 and others and inhibits proliferation of 
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CML cells. Bosutinib like the other TKI cannot override the T315I mutation. The results of the 
phase III Bosutinib Efficacy and Safety in newly diagnosed, chronic-phase myeloid LeukemiA 
(BELA) clinical trial was recently published (Cortes et al., 2012). The primary objective was to 
achieve CCyR rate after one year of treatment. However, the CCyR rate at 12 months for 
bosutinib (70%) was not significantly different than that of imatinib (68%). Though the primary 
objective was not met, patients on bosutinib showed higher major molecular response rate 
(MMR), achieved CCyR and MMR at a faster rate, and had fewer transformations to blast phase. 
Interestingly, recent work from Nathanael Gray’s group at Harvard used a “hybrid-
design” approach to develop inhibitors that are selective for the DFG-out kinase conformation 
(Choi et al., 2012). This new approach combined functionality from dasatinib with moieties from 
imatinib, nilotinib and sorafenib. More specifically, this new class of inhibitors were designed by 
hybridizing the thiazole functionality of dasatinib that interacts with the hinge region with 3-
trifluoromethylbenzamide of imatinib, nilotinib or sorafenib that occupy a region adjacent to the 
ATP-binding site in DFG-out conformations. The new compounds inhibit wild-type and T315I 
BCR-ABL activity.  
Other TKIs are in different stages of clinical trials for CML and include the ABL/LYN 
kinase inhibitor INNO-406 (Bafetinib, CytRx), the ABL/SRC inhibitor AP24534 (Ponatinib, 
Ariad Pharmaceuticals). Another class of inhibitors, known as switch pocket inhibitors (DCC-
2036, DCC-2157; Deciphera Pharmaceuticals), bind to the residues Arg386/Glu282 that are 
involved in switching ABL kinase between active and inactive conformations. DCC-2036 also 
has activity against SFKs. 
In addition to TKIs, Aurora kinase inhibitors such PHA-739358 (dansertib), XL-228, 
KW-2449 among others are in clinical trials for CML. Aurora kinases are serine/threonine 
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kinases involved in different stages of mitosis and have increased expression in myeloid tumors 
and other forms of cancer. These inhibitors that target the kinase’s ATP binding site have shown 
activity against wild-type and T315I ABL (Agrawal et al., 2010).  
1.11 ALLOSTERIC INHIBITORS 
An alternative strategy to overcome imatinib resistance is to target BCR-ABL kinase activity 
through an allosteric site at a distance from the active site. In general, allosteric kinase inhibitors 
are anticipated to target regulatory mechanisms unique to a given kinase and therefore may 
exhibit improved selectivity and reduced off-target effects compared to active inhibitors. 
Using a high-throughput cytotoxicity assay, Gray and coworkers discovered GNF2, the 
first allosteric inhibitor of BCR-ABL (Adrian et al., 2006). Biochemical and structural studies 
showed that GNF2 binds the myristic acid binding pocket of ABL and stabilizes the inactive 
conformation of the kinase. Surprisingly, GNF2 alone was not active against the imatinib-
resistant mutant T315I or several other prominent imatinib-resistant mutants. However, the 
combination of GNF2 with nilotinib was effective at inhibiting the T315I mutant.  In vivo studies 
using a murine bone marrow transplantation model of CML showed that the combination of 
GNF5 (an analog of GNF2 with improved pharmacokinetics) and nilotinib reduced spleen size, 
white blood cell counts and STAT5 phosphorylation while increasing overall survival. In 
addition, HX MS studies revealed conformational changes in the ATP binding site upon GNF5 
binding that directly support allosteric communication between the myristic acid binding pocket 
and the active site, which are separated by more than 30 Å in the crystal structure. Hence, this 
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new class of drug defines and potentiates the development of allosteric inhibitors that could be 
clinically tested (Iacob et al., 2011; Zhang et al., 2010). 
Besides allosteric inhibition by GNF2, peptides that target the BCR-derived region of the 
protein and induced modification of the kinase activity expanded the understanding of allosteric 
inhibitors. Specifically these peptides target the N-terminal coiled-coil region of BCR-ABL and 
inhibit oligomerization, reduce kinase activity and increases sensitivity to both imatinib and 
GNF2 (Beissert et al., 2008). In a more recent study Feng et al. showed that adenoviral 
transduction of SH2-DED (dead effector domain) in CML cells, resulted in its binding to 
pTyr177 through the SH2 domain and activation of Caspase 8 through the DED domain. As a 
result, BCR-ABL positive leukemia cells exhibited reduction in cell proliferation and 
enhancement of apoptosis (Peng et al., 2012).  Whether or not peptide-based approaches such as 
these will ever be translated to the clinic remains unclear.  
1.12 HYPOTHESIS 
Despite the constitutive activation of ABL that results from Bcr fusion, mounting evidence 
suggests that the SH3 and SH2 domains are not necessarily displaced from their regulatory 
positions on the back of the kinase domain.  Mutations in the BCR-ABL SH3 and SH2 domains 
as well as the linker promote imatinib resistance, consistent with the kinase domain adopting the 
active conformation incompatible with drug binding. Similarly, phosphorylation of the BCR-
ABL linker and SH3 domain by the Src-family kinase HCK also results in imatinib resistance, 
most likely by perturbing SH3:linker interaction (Meyn, III et al., 2006; Azam et al., 2003; Pene-
Dumitrescu and Smithgall, 2010). A logical conclusion from these findings is that the SH3 and 
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SH2 domains maintain their regulatory influence on the kinase domain even in the context of 
BCR-ABL. Given the regulatory influence of SH3 on the kinase domain, I propose the 
hypothesis that strengthening the regulatory SH3:linker interaction present in BCR-ABL 
stabilizes a downregulated kinase domain conformation, and sensitizes the kinase domain to both 
imatinib and allosteric inhibitor action. 
An alternate approach to inhibit BCR-ABL mediated signal transduction and oncogenesis 
in imatinib-resistant CML involves small-molecule targeting of Src family kinases (SFKs).  
BCR-ABL binds to and activates multiple SFKs in CML cells, including HCK and LYN. In turn, 
active SFKs directly phosphorylate regulatory tyrosine residues in the ABL SH3 domain, the 
SH2-kinase linker, and the BCR-derived portion of BCR-ABL (Meyn, III et al., 2006). Previous 
work from our group showed that global inhibition of SFK activity with the ATP-competitive 
pyrrolo-pyrimidine A-419259 leads to growth arrest and apoptosis in CML cell lines and in 
primary CD34+ CML cells. In addition, expression of an HCK mutant with engineered 
resistance to A-419259 protects CML cells against the antiproliferative and apoptotic effects of 
this compound (Wilson et al., 2002; Pene-Dumitrescu et al., 2008). Other studies also correlate 
CML progression and drug resistance with overexpression and activation of HCK and LYN (Wu 
et al., 2008). In the latter case, clinical drug resistance was reported in the absence of ABL 
kinase domain mutations. Based on these associations, I propose the hypothesis that imatinib 
resistant ABL mutants may induce cross-resistance to Src-selective inhibitors as a result of cross-
phosphorylation. 
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1.12.1 Specific Aims 
1.12.1.1 Aim 1: Investigate the role of SH3:linker interaction in the regulation of c-
ABL dynamics, signaling, and inhibitor sensitivity. 
In the c-ABL core, the SH2-kinase linker forms a PPII helix that serves as an internal docking 
site for the SH3 domain. This interaction is essential for downregulation of the kinase. However, 
the linker is a suboptimal ligand for the SH3 domain, with two charged lysine residues facing the 
hydrophobic binding surface of SH3. In this aim, I tested the hypothesis that the SH3:linker 
interaction is a key regulator of c-ABL kinase activity and that activating mutations can be 
overcome by enhancing the SH3:linker interaction. To test this hypothesis, it was necessary to 
strengthen the SH3:linker interaction experimentally. In order to achieve tight SH3:linker 
interaction we created a series of ten modified linkers with increasing proline content and termed 
these engineered sequences as “High Affinity Linkers” or HALs for short. Using hydrogen 
exchange mass spectrometry (HX MS), we show that the HAL9 modification enhances 
SH3:linker interaction dramatically. Next, I also determined whether SH3:linker interaction 
allosterically influences the effects of activating mutations in c-ABL core. To do this, I combined 
HAL9 with activating mutations in the myristate-binding pocket (A356N), the gatekeeper at the 
active site (T315I) and in the non-myristoylated (G2A) c-ABL core and expressed the proteins in 
293T cells. Remarkably, the HAL substitution completely reversed ABL core activation by the 
A356N mutation, and partially reversed the effect of T315I and G2A. Next, I investigated 
whether HAL9 resensitizes imatinib resistant BCR-ABL mutants to inhibition by compounds 
that target the kinase domain active site and the allosteric binding pocket using transformed 
human myeloid cells as a model system.  Surprisingly, enhanced SH3:linker interaction also 
dramatically sensitized the BCR-ABL tyrosine kinase associated with CML to small molecule 
 49 
inhibitors. Using HX MS we also show that there is allosteric network linking the SH3 domain, 
the myristic acid binding pocket, and the active site of the c-ABL core, providing a structural 
basis for the biological observations. 
 
1.12.1.2 Aim 2: Determine the mechanism of cross-resistance of SFKs to the Src-
selective inhibitor A-419259 in cells transformed with the BCR-ABL imatinib-resistant 
mutant, T315I. 
Given the important role of SFKs in BCR-ABL-mediated signaling and drug resistance, I studied 
the effect of the SFK inhibitor A-419259 on human TF-1 myeloid cells transformed with 
clinically relevant imatinib-resistant mutants of BCR-ABL (E255V, Y253H and T315I). The 
anti-proliferative effects of the inhibitor correlated with suppression of overall SFK activity. 
However, TF-1 cells transformed with the gatekeeper mutant T315I were completely cross-
resistant to A-419259 and endogenous SFK activity was not inhibited. These data suggest a new 
mechanism of BCR-ABL T315I-induced resistance to drugs that target SFKs in CML. In this 
aim, I explored the possibility that BCR-ABL T315I-induced resistance to drugs that target SFKs 
in CML is due to an acquired ability of BCR-ABL T315I to phosphorylate SFKs at novel sites 
that interfere with drug action.  
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2.0  ENHANCED SH3:LINKER INTERACTION ALLOSTERICALLY SENSITIZES 
ABL KINASES TO SMALL MOLECULE INHIBITORS 
2.1 ABSTRACT 
 
Multi-domain kinases such as c-SRC and c-ABL are regulated by complex allosteric 
interactions involving their non-catalytic SH3 and SH2 domains. In this study we show 
that enhancing natural  allosteric  control  of  kinase  activity  by  SH3:linker   engagement  
has  long-range suppressive effects on the kinase activity of the c-ABL core.  Surprisingly, 
enhanced SH3:linker interaction also dramatically sensitized the BCR-ABL tyrosine kinase 
associated with CML to small molecule inhibitors that target either the active site or the 
myristic acid binding pocket in the kinase  domain  C-lobe.  Dynamics analyses using 
hydrogen exchange mass spectrometry revealed a remarkable allosteric network linking the 
SH3 domain, the myristic acid binding pocket, and the active site of the c-ABL core, 
providing a structural basis for the biological observations. These results suggest a rational 
strategy for enhanced drug targeting of BCR-ABL and other multi-domain kinase systems that 
uses small molecules to exploit natural mechanisms of kinase control. 
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2.2 INTRODUCTION 
 
Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome 
translocation, which fuses the BCR (break point cluster) region locus on chromosome 22 with 
the c-ABL (Abelson tyrosine kinase) proto-oncogene on chromosome 9. This translocation results 
in the expression of BCR-ABL, a constitutively active protein-tyrosine kinase that drives CML 
pathogenesis through downstream pathways that promote cell growth and survival. Expression of 
BCR-ABL in bone marrow cells induces a CML-like syndrome in mouse models, demonstrating 
BCR-ABL kinase activity alone is sufficient to cause the disease (Wong and Witte, 2004; 
Hantschel and Superti-Furga, 2004).  
Clinical management of CML has been revolutionized by imatinib mesylate, a selective 
ATP-competitive inhibitor of BCR-ABL kinase activity (Druker, 2004).  Despite this clinical 
success, imatinib is less effective in advanced CML due to selection of drug resistant mutants of 
BCR-ABL (Nardi et al., 2004). Resistance mutations often arise in the drug binding site, and 
include the T315I gatekeeper mutation that also enhances BCR-ABL kinase and transforming 
activities (Griswold et al., 2006). Other mutations occur outside of the active site and 
allosterically reduce drug binding by promoting an active kinase domain conformation 
incompatible with imatinib binding. Second generation ATP-competitive inhibitors, including 
nilotinib and dasatinib; have been approved for the clinical management of imatinib-resistant 
CML (Rix et al., 2007). While these newer inhibitors are more potent, they do not inhibit the 
BCR-ABL T315I mutant.  
In contrast to BCR-ABL, c-ABL kinase activity is tightly regulated in cells. Structural 
and functional studies attribute intramolecular interactions to downregulation of the c-ABL 
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kinase core, which consists of a myristoylated N-terminal region (NCap), followed by regulatory 
SH3 and SH2 domains, the SH2-kinase linker and the kinase domain (Nagar et al., 2006).  The 
kinase domain is comprised of a smaller N-lobe connected to a larger C-lobe through a flexible 
hinge, allowing for articulation of the two lobes during kinase activation.  The NCap, SH3 and 
SH2 domains work in concert to keep the kinase in the autoinhibited state (Nagar et al., 2003; 
Nagar et al., 2006; Hantschel et al., 2003). By binding to the SH2-kinase linker through an 
atypical PxxP motif (P242TVY245), the SH3 domain stabilizes the N-lobe of the kinase domain in 
the inactive state.  Mutations within the SH3 domain, as well as the linker, switch on the kinase 
and transforming activities of c-ABL (Barila and Superti-Furga, 1998).  Moreover, 
phosphorylation of residues in the linker (Tyr245) or in the SH3 domain (Tyr89) disrupt 
SH3:linker engagement and also enhance ABL kinase activity (Chen et al., 2008b; Meyn, III et 
al., 2006).  The SH2 domain docks onto the back of the kinase domain C-lobe through a network 
of hydrogen bonds to further stabilize the downregulated conformation of the core. Mutation of 
SH2 Tyr158 disturbs this interaction and leads to kinase activation (Hantschel et al., 2003). 
Finally, the N-terminal myristate group penetrates into a deep pocket in the C-lobe, inducing a 
kink in helix αI that is critical for SH2:C-lobe interaction. Mutations in the hydrophobic pocket 
of the C-lobe that prevent myristic acid insertion (e.g. A356N) activate the kinase. Recently, a 
new class of allosteric BCR-ABL inhibitors has been described that target the C-lobe myristic 
acid binding site (Adrian et al., 2006; Zhang et al., 2010).  These compounds, of which GNF-2 is 
the prototype, stabilize the inactive conformation of the ABL core and work in concert with 
ATP-competitive inhibitors to overcome imatinib-resistant mutants of BCR-ABL, including 
T315I (Zhang et al., 2010; Iacob et al., 2011). 
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In the context of BCR-ABL, BCR fusion prevents N-terminal myristoylation of c-ABL, 
thereby removing one important element of kinase downregulation. In addition, BCR adds an N-
terminal coiled-coil oligomerization domain that induces clustering of BCR-ABL and promotes 
kinase activation through trans-phosphorylation of the activation loop (McWhirter et al., 1993). 
Unlike the c-ABL core, the contribution of the SH3 and SH2 domains to kinase domain control 
within BCR-ABL is less clear. Despite the constitutive activation of ABL that results from BCR 
fusion, mounting evidence suggests that the SH3 and SH2 domains are not necessarily displaced 
from their regulatory position on the back of the kinase domain. Experimental and clinical 
mutations in the BCR-ABL SH3 and SH2 domains as well as the linker promote imatinib 
resistance, consistent with the kinase domain adopting the active conformation incompatible with 
drug binding (Azam et al., 2003). Similarly, phosphorylation of the BCR-ABL linker and SH3 
domain by the Src-family kinase HCK also results in imatinib resistance, most likely by 
perturbing SH3:linker interaction (Pene-Dumitrescu and Smithgall, 2010). A logical conclusion 
from these findings is that the SH3 and SH2 domains maintain their regulatory influence on the 
kinase domain even in the context of BCR-ABL. This raises the exciting possibility that 
strengthening the regulatory SH3:linker interaction present in BCR-ABL may stabilize a single 
downregulated kinase domain conformation, thus sensitizing the kinase domain to both imatinib 
and allosteric inhibitor action. 
In this study, we explored this possibility by creating a series of modified c-ABL and 
BCR-ABL proteins with enhanced SH3:linker interactions.  By systematically increasing the 
proline content of the linker, we identified high-affinity linkers that stabilized intramolecular 
SH3:linker binding without disturbing the overall regulation of the kinase core.  Enhanced 
SH3:linker interaction completely reversed c-ABL core activation by a C-lobe myristate binding 
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pocket mutation, and substantially reduced activation by mutations in the ATP binding site 
(T315I) as well as the SH2:C-lobe interface (Y158D). Remarkably, enhanced SH3:linker 
interaction dramatically sensitized BCR-ABL not only to imatinib but also to the allosteric 
inhibitor, GNF-2. These effects were observed in the context of both wild-type and imatinib-
resistant forms of BCR-ABL.  Hydrogen exchange mass spectrometry of recombinant ABL core 
proteins with high-affinity linkers revealed a previously unrecognized dynamic coupling between 
the SH3:linker interface and the GNF-2 binding site in the C-lobe myristate binding pocket.  
Taken together, these studies provide strong evidence that regulatory SH3:linker interaction is 
retained in the context of BCR-ABL, and that overall kinase regulation is controlled by an 
‘allosteric triangle’ linking the SH3 domain, the C-lobe, and the active site. Small molecules 
enhancing natural regulatory interaction at the SH3:linker interface may have clinical utility as 
chemical sensitizers of existing BCR-ABL drug action. 
2.3 RESULTS 
 
2.3.1 Design and characterization of High Affinity Linker (HAL) variants of ABL 
 
In the context of the c-ABL core, the SH2-kinase linker forms a polyproline type II (PPII) helix 
that serves as an internal docking site for the SH3 domain. This interaction is essential to 
downregulation of c-ABL activity. Compared with high affinity peptide ligands for the ABL 
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SH3 domain (Pisabarro et al., 1998), however, the linker represents a suboptimal SH3 docking 
site, with a charged residue (lysine) facing the hydrophobic binding surface of SH3 (Figure 5). In 
order to strengthen internal SH3:linker interaction, we systematically substituted linker residues 
in close proximity with the SH3 surface with prolines, resulting in a set of 10 modified linkers 
(see Figure 6A for sequences). These engineered sequences are referred to hereafter as high 
affinity linkers (HALs).  
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Figure 5: Model of c-ABL core with enhanced SH3:linker interface. Model of the downregulated wild-type c-
ABL core is shown at the top left, and includes the NCap (light blue), SH3 domain (red), SH2 domain (green), SH2-
kinase linker (orange), and kinase domain (purple).  The SH3:linker interface (boxed) is enlarged on the right to 
highlight the side chains of the linker residues that were modified in the HAL9 mutant. Models of the c-ABL HAL9 
core protein and SH3:linker interface are shown in the lower panels, in which proline residues were substituted for 
five wild-type residues shown at the top. Models and residue numbering is based on the X-ray crystal structure of 
the myristoylated c-ABL core (PDB: 2FO0) and PyMol.  
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To determine whether increased proline content stabilized intramolecular SH3 binding, 
the modified linkers were first incorporated into bacterial expression vectors for the Abl SH3-
SH2-linker region. The resulting proteins were expressed, purified and examined for enhanced 
SH3:linker interaction using hydrogen exchange mass spectrometry (HX MS), a method 
previously developed to explore the impact of linker engagement on ABL SH3 dynamics (Chen 
et al., 2008b; Chen et al., 2008a). With HX MS, protein dynamics are determined by measuring 
the rate of backbone amide hydrogen exchange following transfer to a deuterated solvent (Wales 
and Engen, 2006). Under physiological conditions, HX MS has shown that the c-ABL SH3 
domain undergoes a cooperative partial unfolding event which is stabilized by ligand binding 
either in cis (linker) or in trans (high affinity peptide). The extent of SH3 unfolding is directly 
proportional to the affinity of the ligand, and complete inhibition of SH3 unfolding can be 
achieved by binding to the BP1 peptide, a sequence with relatively high affinity towards the 
ABL SH3 domain (Chen et al., 2008b; Chen et al., 2008a). HX MS measurements provide a 
direct assay for the impact of the HAL substitutions on intramolecular SH3 engagement.  
HX MS was performed on the wild-type ABL SH3-SH2-linker protein as well as all ten 
recombinant HAL mutants, and the results are summarized in Figure 6B.  Introduction of single 
proline residues in the so-called P0 or P+3 (HAL1; HAL2) positions alone, which directly oppose 
the SH3 domain in the downregulated structure of the c-ABL core (Figure 5), did not alter SH3 
unfolding relative to the wild-type protein. However, double proline substitution at both of these 
positions (HAL3) showed a moderate increase in the SH3 unfolding half-life compared to the 
wild type and singly substituted linkers, although this effect was subtle (about 2-fold; Figure 6B). 
Substitution of prolines at the P+1 (HAL4) and P-2 (HAL5) positions, either individually or in 
combination (HAL6), did not increase SH3:linker engagement, nor did addition of the P+1 
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proline to the HAL3 protein (HAL7).  However, sequential addition of prolines to HAL7 at the 
P-2 (HAL8) and P-3 (HAL9) positions resulted in dramatic increases to the unfolding half-life of 
about 5-fold and 7-fold for HAL8 and HAL9, respectively. Addition of one final proline to 
HAL9 at position P-4 (HAL10) completely suppressed cooperative unfolding, suggesting that the 
SH3 domain is essentially locked to this modified linker.  
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Figure 6: Linker proline substitutions enhance SH3 engagement. A) The sequence of the wild-type c-ABL 
linker is aligned with each of the ten HAL sequences as well as the linker of the Src-family kinase, HCK. Proline 
substitutions introduced into each of the HAL sequences are highlighted in red.  B) Analysis of intramolecular 
SH3:linker interaction by HXMS.  Recombinant c-ABL proteins consisting of the NCap, SH3 and SH2 domains 
plus each of the linkers shown were expressed in bacteria, purified, and subjected to HX MS analysis as described in 
the text. Data are expressed as the unfolding half-life of the SH3 domain which is directly proportional to the 
strength of the internal SH3-linker interaction. 
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We next introduced all ten HAL sequences into a c-ABL kinase core protein composed of 
the NCap, the SH3 and SH2 domains, the SH2-kinase linker and the kinase domain. The X-ray 
crystal structure of this core protein has been determined previously and it contains all of the 
structural elements necessary for downregulation (Nagar et al., 2006).  To determine the impact 
of the HAL sequences on ABL kinase activity, the wild-type and HAL core proteins were 
expressed in 293T cells, immunoprecipitated and immunoblotted with antibodies against key 
phosphotyrosine residues in the activation loop (pTyr412), the SH2-kinase linker (pTyr245) and 
in the SH3 domain (pTyr89).  As shown in Figure 7A, ABL core proteins with HAL sequences 
1, 4, 6, 8 and 9 were phosphorylated at each of these sites to the same or reduced levels relative 
to wild-type ABL, suggesting that these modified linkers adopt a PPII helical conformation 
compatible with downregulation of the wild-type ABL kinase core (Figure 5). As an independent 
measure of kinase activity, we also assessed levels of tyrosine phosphoproteins in lysates from 
the transfected cells. As shown in Figure 7B, the extent of protein-tyrosine phosphorylation in 
the cell lysates parallels the level of phosphorylation at each of the regulatory tyrosines in each c-
ABL core protein.  A quantitative analysis of regulatory site phosphorylation is presented in 
Figure 7C. 
In contrast, ABL core proteins with HAL substitutions 2, 3, 5, and 7 showed much higher 
phosphorylation of autoregulatory tyrosine sites and a concomitant increase in cellular 
phosphotyrosine content (Figure 7).  The HAL10 core protein also appeared to be upregulated, 
albeit to a lesser extent.  While the HXMS studies show that the HAL10 substitutions strongly 
enhances SH3 domain interaction, it must also produce additional changes to the linker structure 
that interfere with its ability to contact the kinase domain to effectively downregulate kinase 
activity.   
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Figure 7: ABL-HAL core protein expression and relative kinase activity. A) Each of the HAL sequences shown 
in Figure 6A were introduced into the c-ABL kinase core, consisting of the NCap, the SH3 and SH2 domains, the 
SH2-kinase linker, and the kinase domain. Each ABL core proteins was expressed in 293T cells, 
immunoprecipitated, and immunoblotted with phosphospecific antibodies against phosphotyrosine residues in the 
activation loop (pY412), the SH2-kinase linker (pY245) and the SH3 domain (pY89) as well as for ABL protein 
recovery.  B) Overall protein-tyrosine phosphorylation was assessed in the cell lysates by immunoblotting; ABL 
blots were also performed as a control. C) The phosphotyrosine signal intensities from two independent experiments 
were normalized to the levels obtained with wild-type ABL, and the results are presented as fold change ± S.D.  
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2.3.2 Enhanced SH3:linker interaction overcomes ABL core activation by 
gatekeeper and myr-binding pocket mutations 
Previous studies have shown that the ABL “gatekeeper” mutant associated with imatinib 
resistance (T315I) is much more active in vitro than the corresponding wild-type kinase. 
Furthermore, mutations of the N-terminal c-ABL myristoylation site or the complementary 
myristate binding pocket in the kinase domain C-lobe (e.g., A356N) strongly upregulate ABL 
kinase activity (Hantschel et al., 2003). These observations led us to explore whether enhanced 
SH3:linker interaction could reverse these activating influences through an allosteric mechanism. 
To test this possibility, we first confirmed the activating effects of these ABL mutations using 
the 293T cell expression system. Three ABL core protein mutants were expressed: the T315I 
gatekeeper mutant, a myristoylation-defective mutant in which the essential N-terminal glycine 
is replaced with alanine (G2A), and the myristic acid binding pocket mutant (A356N) described 
above. As shown in Figure 8, all three mutations strongly enhanced the phosphorylation of the 
activation loop (pY412), linker (pY245) and SH3 domain (pY89) regulatory sites and resulted in 
a parallel increase in overall protein-tyrosine phosphorylation in cell lysates.  
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Figure 8: Activating mutations of the ABL-core protein.  A) Model of the downregulated, myristoylated c-ABL 
core showing the positions of key tyrosine autophosphorylation sites in the SH3 domain (Tyr89), SH2-kinase linker 
(Tyr245) and kinase domain activation loop (Tyr412).  The positions of three activating mutations are also shown, 
which involve Ile substitution for the gatekeeper residue (Thr315), Asn substitution for Ala356 in the myristate 
binding pocket, and substitution of Gly2 with Ala, which prevents myristoylation. (Numbering is based on the 
crystal structure of the c-ABL core (PDB: 2FO0) with the exception of the gatekeeper residue, which is numbered as 
Thr315 by convention; this position corresponds to Thr334 in structure 2FO0.  B) The wild-type (WT) c-ABL core 
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and active mutants described in part A (T315I, A356N, and G2A) were expressed in 293T cells, 
immunoprecipitated, and immunoblotted with phosphospecific antibodies against pY412, pY245 and pY89 as well 
as for ABL protein recovery.  Untransfected cells served as the negative control.  C) Overall protein-tyrosine 
phosphorylation was assessed in the cell lysates by immunoblotting; ABL blots were also performed as a control. 
 
To determine whether enhanced SH3:linker interaction influences the effect of activating 
mutations in the ABL core, we combined all ten HAL sequences with the myristate-binding 
pocket mutation (A356N). We then expressed these proteins in 293T cells and looked for 
changes in autophosphorylation of the three regulatory tyrosines.  As shown in Figure 9, HAL9 
completely reversed the potent activating effects of the A356N mutation as judged by the 
reduced phosphorylation of all three tyrosine sites. In addition, the overall phosphotyrosine 
content of lysates from cells expressing ABL-HAL9-A356N is dramatically reduced. These data 
support the idea that SH3:linker interaction allosterically overrides the activating effect of the 
myristic acid binding pocket mutation. 
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Figure 9: HAL9 completely suppresses c-ABL activation caused by myristic acid binding pocket mutation 
(A356N).  A) Each of the ten HAL sequences was combined with the A356N mutation in the c-ABL core and the 
resulting compound mutants were expressed in 293T cells. ABL proteins were immunoprecipitated and 
immunoblotted with phosphospecific antibodies against the activation loop (pY412), the SH2-kinase linker (pY245) 
and the SH3 domain (pY89) as well as for Abl protein recovery.  B) Overall protein-tyrosine phosphorylation was 
assessed in the cell lysates by immunoblotting; ABL blots were also performed as a control. C) The phosphotyrosine 
signal intensities from three independent experiments were normalized to the levels obtained with the A356N ABL 
mutant with a wild-type linker, and the results are presented as fold change ± S.D.  
 66 
We next combined each of HAL sequences with the myristoylation-defective ABL core 
mutant, G2A.  Compared to ABL A356N, HAL9 substitution partially reversed the activating 
effects of this mutation both in terms of autophosphorylation and cell protein phosphorylation 
(Figure 10).  This result suggests that disruption of myr-NCap interaction with the kinase domain 
C-lobe by mutating the myristoylation site results in a different active state of the ABL core 
compared to mutation of the myristic acid binding pocket. 
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Figure 10: HAL9 partially reverses c-ABL activation caused by myristoylation signal sequence mutation 
(G2A).  A) Each of the ten HAL sequences was combined with the G2A mutation in the myristoylation signal 
sequence of the c-ABL core, and the resulting compound mutants were expressed in 293T cells. ABL proteins were 
immunoprecipitated and immunoblotted with phosphospecific antibodies against the activation loop (pY412), the 
SH2-kinase linker (pY245) and the SH3 domain (pY89) as well as for ABL protein recovery.  B) Overall protein-
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tyrosine phosphorylation was assessed in the cell lysates by immunoblotting; ABL blots were also performed as a 
control. C) The phosphotyrosine signal intensities from two independent experiments were normalized to the levels 
obtained with the G2A ABL mutant with a wild-type linker, and the results are presented as fold change ± S.D.  
 
We have previously observed that the activating gatekeeper mutation in the c-ABL core 
(T315I) causes local conformational changes in the kinase domain and at a distance in the SH3 
domain. To investigate whether enhanced SH3:linker interaction impacted the activating effect 
of the gatekeeper mutation, we combined all ten HAL sequences with T315I and determined 
their relative activity in 293T cells. As shown in Figure 11, HAL9 reversed ABL core T315I 
activation loop tyrosine phosphorylation (pTyr412) by more than 60%, while phosphorylation of 
the linker (pTyr245) and SH3 domain (pTyr89) was completely suppressed. Consistent with 
these observations, HAL9 substitution also substantially reduced cellular phosphotyrosine 
content.  These results show that the destabilizing impact of ABL gatekeeper mutation on the 
ABL kinase domain remains under the allosteric control of SH3:linker interaction. 
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Figure 11: HAL9 suppresses c-ABL activation caused by gatekeeper mutation (T315I).  A) Each of the ten 
HAL sequences was combined with the T315I gatekeeper mutation in the c-ABL kinase domain, and the resulting 
compound mutants were expressed in 293T cells. ABL proteins were immunoprecipitated and immunoblotted with 
phosphospecific antibodies against the activation loop (pY412), the SH2-kinase linker (pY245) and the SH3 domain 
(pY89) as well as for ABL protein recovery.  B) Overall protein-tyrosine phosphorylation was assessed in the cell 
lysates by immunoblotting; ABL blots were also performed as a control. C) The phosphotyrosine signal intensities 
from two independent experiments were normalized to the levels obtained with the T315I ABL mutant with a wild-
type linker, and the results are presented as fold change ± S.D. 
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2.3.3 Enhanced SH3:linker interaction overcomes ABL kinase activation by SH2-
kinase interface mutation 
The interface of the SH2 and kinase domain C-lobe is also important for auto-inhibition of the c-
ABL kinase. In the X-ray crystal structure of the downregulated core, Tyr158 in the SH2 domain 
makes a pi-stacking interaction with Tyr361 of kinase domain helix αE and is also hydrogen 
bonded to Asn393 (Nagar et al., 2003; Nagar et al., 2006). Substitution of SH2 Tyr158 with 
aspartate (Y158D) has been shown to increase ABL kinase activity, presumably by disturbing 
this interaction. To determine whether enhanced SH3:linker interaction influences the activating 
effects of the Y158D mutation, the HAL9 sequence was combined with this SH2 mutation in the 
c-ABL core. As shown in Figure 12, the Y158D mutation alone strongly enhanced 
autophosphorylation of regulatory tyrosines 412, 89 and 245, and enhanced the phosphorylation 
of cellular proteins. Remarkably, introduction of the HAL9 sequence almost completely reversed 
the activation resulting from this SH2 domain mutation. Activation loop phosphorylation was 
suppressed by 80%, while phosphorylation of the regulatory SH3 and linker tyrosines was almost 
completely suppressed. The presence of HAL9 also significantly reduced overall protein-tyrosine 
phosphorylation in lysates from cells expressing this mutant. These data show that enhanced 
SH3-linker interaction overcomes the activating effect of disturbing the SH2:kinase domain 
interaction, and reveal an allosteric connection between the SH3:linker and SH2:C-lobe.  
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Figure 12: HAL9 substitution suppresses c-ABL core activation by SH2-kinase interface mutation (Y158D).  
A) Model of the c-ABL core highlighting tyrosine residues in the SH2 domain (Tyr158) and kinase domain C-lobe 
(Tyr361) that interact as part of the downregulated conformation.  B) The wild-type c-ABL core protein (WT), 
HAL9, the SH2 Tyr158 to aspartate mutant (Y158D), as well as the compound mutant (HAL9-YD) were expressed 
in 293T cells. Untransfected cells were included as a negative control.  ABL proteins were immunoprecipitated and 
immunoblotted with phosphospecific antibodies against the activation loop (pY412), the SH2-kinase linker (pY245) 
and the SH3 domain (pY89) as well as for ABL protein recovery.  C) Overall protein-tyrosine phosphorylation was 
assessed in the cell lysates by immunoblotting; ABL blots were also performed as a control. This experiment was 
repeated twice and produced comparable results; a representative example is shown. 
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2.3.4 High affinity linkers sensitize BCR-ABL-transformed cells to imatinib-
induced apoptosis 
Structural and biochemical data have established that imatinib inhibits BCR-ABL by stabilizing 
the inactive conformation of the kinase domain, which provides the basis for some of its kinase 
selectivity. Results presented so far show that enhanced SH3:linker interaction suppresses ABL 
kinase activity, suggesting that the HAL sequence may stabilize the inactive ABL kinase domain 
conformation and enhance imatinib sensitivity.  To test this idea, we transformed human TF-1 
myeloid cells with the wild-type and HAL9 forms of BCR-ABL. Each transformed cell 
population was then treated with imatinib at concentrations ranging from 0.03 to 1 µM for 48 
hours, followed by assays for effector caspase activation and cell viability.  As shown in Figure 
13A, TF-1 cells transformed with wild-type BCR-ABL showed a dose-dependent increase in 
apoptosis following imatinib treatment. When this experiment was repeated with cells expressing 
BCR-ABL-HAL, the apparent potency of imatinib was increased, supporting the idea that 
enhanced SH3-linker interaction stabilizes the “DFG-out” kinase domain conformation required 
for imatinib binding.  Immunoblots for BCR-ABL activity were consistent with the apoptosis 
data, showing enhanced sensitivity to imatinib at the activation loop (pY412), the SH3 domain 
(pY89) and in overall tyrosine phosphorylation of proteins in cell lysates (Figure 13B). In 
contrast, HAL9 substitution did not sensitize TF-1 cells transformed with BCR-ABL T315I 
responded to imatinib, even at concentrations as high as 10 µM (Figure 14).  This is consistent 
with the steric clash and loss of the T315 H-bond to imatinib that results from the T315I 
mutation (Gorre et al., 2001).   
 72 
0.
00
0.
03
0.
10
0.
30
0.
60
1.
00
0.0
0.3
0.6
0.9
1.2
WT
HAL9
A
po
pt
os
is
:V
ia
bi
lit
y
R
at
io
BCR-ABL
pY412
pY89
pTyr
WT HAL9
0   0.1 0.3  1  3   0  0.1 0.3 1   3
Imatinib (µM)
A
B
 
Figure 13: HAL9 sensitizes BCR-ABL-transformed cells to imatinib-induced apoptosis.  A) Human TF-1 
myeloid cells were transduced with BCR-ABL retroviruses with either wild-type (WT) or high-affinity (HAL9) 
SH2-kinase linkers.  Transformed cells were plated in triplicate wells in the presence of the indicated concentrations 
of imatinib for 48 h. Apoptosis (assayed as Caspase3/7 activity) and cell viability were measured simultaneously as 
described under Materials and Methods.  Apoptosis data were normalized to viable cell number and are presented in 
the bar graph as the average of three independent experiments performed in each of two independently transformed 
cell lines.  B) TF-1 cells transformed with wild-type (WT) or HAL9 BCR-ABL were treated with the indicated 
concentrations of imatinib for 16 h. Cell lysates were immunoblotted with antibodies to the BCR-ABL protein, 
phosphospecific antibodies for the BCR-ABL activation loop (pY412) and SH3 domain (pY89), and for overall 
levels of protein tyrosine phosphorylation (pTyr). 
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Figure 14: HAL9 does not affect imatinib-induced apoptosis in myeloid cells transformed with BCR-ABL 
T315I.  A) Human TF-1 myeloid cells were transduced with BCR-ABL T315I retroviruses with either wild-type 
(T315I) or high-affinity (T315I-HAL9) SH2-kinase linkers.  Transformed cells were plated in triplicate wells in the 
presence of the indicated concentrations of imatinib for 48 h. Apoptosis (assayed as Caspase3/7 activity) and cell 
viability were measured simultaneously as described under Materials and Methods.  Apoptosis data were normalized 
to viable cell number and are presented in the bar graph as the average of three independent experiments performed 
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in each of two independently transformed cell lines.  B) TF-1 cells transformed with the T315I or T315I-HAL9 
forms of BCR-ABL were treated with the indicated concentrations of imatinib for 16 h. Cell lysates were 
immunoblotted with antibodies to the BCR-ABL protein, phosphospecific antibodies for the BCR-ABL activation 
loop (pY412) and SH3 domain (pY89), and for overall levels of protein tyrosine phosphorylation (pTyr). 
 
2.3.5 High affinity linkers sensitize BCR-ABL-transformed cells to the allosteric 
kinase inhibitors 
Recent studies have identified a novel class of BCR-ABL inhibitors that interact with the 
myristic acid binding pocket in the C-lobe of the kinase domain (Adrian et al., 2006; Zhang et 
al., 2010). Structural and dynamics studies show that these inhibitors, of which the 
phenylaminopyrimidine compound GNF-2 is the prototype, stabilize the active site of the kinase 
through an allosteric mechanism (Zhang et al., 2010; Iacob et al., 2011). These observations led 
us to investigate whether HAL substitution also enhances the sensitivity of BCR-ABL-
transformed TF-1 cells to allosteric inhibitors such as GNF-2. We first evaluated the sensitivity 
of TF-1 cells transformed with the wild-type and HAL9 forms of BCR-ABL to GNF-2 treatment 
(Figure 15A). In this case, the presence of the high affinity linker dramatically enhanced the 
apoptotic response to GNF-2, with half-maximal induction of apoptosis at 200 nM.  In contrast, 
cells transformed with wild-type BCR-ABL were much less sensitive to GNF-2, with an IC50 
value of at least 10 µM. Immunoblots for BCR-ABL  kinase activity closely parallel the 
apoptosis results, with nearly complete inhibition of BCR-ABL-HAL9 kinase activity with as 
little as 100 nM GNF-2 (Figure 15B).  These results support an allosteric connection between the 
SH3 domain and the myristic acid binding pocket, and show that inhibitors targeting this C-lobe 
binding site are sensitive to the overall conformation of the ABL kinase domain. 
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Although the binding site for GNF-2 is localized to the C-lobe of the kinase domain, the 
imatinib-resistant BCR-ABL mutant T315I is also insensitive to this allosteric inhibitor. Given 
the strong sensitizing effect of the HAL substitution on the apoptotic response to GNF-2 in wild-
type BCR-ABL, we repeated these experiments using TF-1 cells transformed with BCR-ABL 
T315I bearing either a wild-type linker or the HAL9 substitution. As shown in Figure 16A, 
HAL9 substitution markedly enhanced the sensitivity of TF-1 cells transformed with BCR-ABL 
T315I to the apoptotic effects of GNF-2, although the impact was not as strong as that observed 
for wild-type BCR-ABL. Immunoblots for BCR-ABL T315I kinase activity also show the 
influence of the HAL9 substitution on GNF-2 sensitivity (Figure 16B). This result shows that 
enhanced SH3:linker interaction can influence the T315I kinase domain conformation in the 
context of BCR-ABL.  Very similar results were obtained with the second-generation analog, 
GNF-5, for which in vivo efficacy has recently been demonstrated (Figure 17). 
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Figure 15: HAL9 sensitizes BCR-ABL-transformed cells to GNF-2-induced apoptosis.  A) Human TF-1 
myeloid cells were transduced with BCR-ABL retroviruses with either wild-type (WT) or high-affinity (HAL9) 
SH2-kinase linkers.  Transformed cells were plated in triplicate wells in the presence of the indicated concentrations 
of GNF-2 for 48 h. Apoptosis (assayed as Caspase3/7 activity) and cell viability were measured simultaneously as 
described under Materials and Methods.  Apoptosis data were normalized to viable cell number and are presented in 
the bar graph as the average of three independent experiments performed in each of two independently transformed 
cell lines.  B) TF-1 cells transformed with wild-type (WT) or HAL9 BCR-ABL were treated with the indicated 
concentrations of GNF-2 for 16 h. Cell lysates were immunoblotted with antibodies to the BCR-ABL protein, 
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phosphospecific antibodies for the BCR-ABL activation loop (pY412) and SH3 domain (pY89), and for overall 
levels of protein tyrosine phosphorylation (pTyr). 
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Figure 16: HAL9 sensitizes myeloid cells transformed with BCR-ABL T315I to GNF-2-mediated apoptosis.  
A) Human TF-1 myeloid cells were transduced with BCR-ABL T315I retroviruses with either wild-type (T315I) or 
high-affinity (T315I-HAL9) SH2-kinase linkers.  Transformed cells were plated in triplicate wells in the presence of 
the indicated concentrations of GNF-2 for 48 h. Apoptosis (assayed as Caspase3/7 activity) and cell viability were 
measured simultaneously as described under Materials and Methods.  Apoptosis data were normalized to viable cell 
number and are presented in the bar graph as the average of three independent experiments performed in each of two 
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independently transformed cell lines.  B) TF-1 cells transformed with the T315I or T315I-HAL9 forms of BCR-
ABL were treated with the indicated concentrations of GNF-2 for 16 h. Cell lysates were immunoblotted with 
antibodies to the BCR-ABL protein, phosphospecific antibodies for the BCR-ABL activation loop (pY412) and SH3 
domain (pY89), and for overall levels of protein tyrosine phosphorylation (pTyr). 
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Figure 17: HAL9 sensitizes wild-type and T315I BCR-ABL-transformed cells to GNF-5-induced apoptosis. 
Human TF-1 myeloid cells were transduced with wild-type (WT; top) or T315I (bottom) BCR-ABL retroviruses with 
either wild-type or high-affinity (HAL9) SH2-kinase linkers as indicated. Transformed cells were plated in triplicate 
wells in the presence of the indicated concentrations of GNF-2 for 48 h. Apoptosis (assayed as Caspase3/7 activity) 
and cell viability were measured simultaneously as described under Materials and Methods.  Apoptosis data were 
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normalized to viable cell number and are presented in the bar graph as the average of three independent experiments 
performed in each of two independently transformed cell lines.   
2.3.6 Hydrogen exchange mass spectrometry (HXMS) supports allosteric interplay 
between the SH3 domain, the GNF-2 binding pocket and the active site of the c-Abl core 
Results presented above demonstrate that enhanced SH3:linker interaction completely suppresses 
the activity of a c-ABL core domain myristate binding pocket mutant (A356N; Figure 9), and 
dramatically enhances the sensitivity of BCR-ABL to allosteric inhibitors (GNF-2, GNF-5) that 
bind to this C-lobe pocket (Figures 15-17). These findings suggest that the SH3:linker interface 
exerts remarkable allosteric control over the regulatory influence of the C-lobe on the active site. 
To test this possibility from a structural perspective, we investigated global conformational 
changes in recombinant c-ABL kinase core proteins that result from the A356N mutation and 
HAL9 substitution using hydrogen exchange mass spectrometry (HX MS).  
The c-ABL core proteins chosen for comparison include wild-type (WT), the A356N 
mutant, HAL9, and the combined HAL9-A356N protein.  All four proteins were expressed in 
their myristoylated forms using Sf9 cells as the host, and purified to homogeneity. The intact 
mass of each protein was determined, and showed that the WT and HAL9 proteins were largely 
unphosphorylated, while the A356N mutant was heavily phosphorylated, consistent with the 
activating effect of this mutation (Figure 18).  Interestingly, HAL9 substitution nearly reversed 
autophosphorylation of A356N, supporting the dominant allosteric control of enhanced 
SH3:linker interaction on overall kinase activity. 
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Figure 18: Mass analysis of recombinant c-ABL core proteins.  Wild-type c-ABL core (WT), A356N, HAL9 and 
A356N-HAL9 proteins were overexpressed in Sf9 insect cells together with the Yersinia phosphatase, YopH, as 
described previously for the wild-type c-ABL core (Iacob et al., 2009). For intact protein mass spectral analysis, 
each protein was injected onto a POROS 20 R2 protein trap and desalted with 0.05% trifluroacetic acid (TFA) at a 
flow rate of 100 µL/min. The proteins were eluted into the mass spectrometer, using a linear 15-75% (vol/vol) 
acetonitrile gradient over 4 min at 50 µL/min and a Shimadzu HPLC system (LC-10ADvp). Intact protein analyses 
were performed on an LCT-Premier instrument (Waters) equipped with a standard electrospray source. The capillary 
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voltage was 3.2 kV and the cone voltage was 35 V. Nitrogen was used as desolvation gas.  A source temperature of 
175 °C and a desolvation temperature of 80 °C were applied. The instrument was calibrated by infusing a solution of 
500 fmol/µL myoglobin and the mass accuracy was 10 ppm.  The raw m/z data are shown on the left and the 
transformed, mass-only spectra are shown on the right. The measured and theoretical molecular masses are 
indicated, and the additional + 80 Da peaks correspond to tyrosine phosphorylated species. All masses are consistent 
with stoichiometrically myristoylated proteins. 
 
For HX MS experiments, each recombinant ABL core protein was diluted into D2O-
based buffer, and aliquots were removed at various time points followed by rapid quenching.  In 
order to refine to location of deuterium incorporation, each protein was digested with pepsin 
prior to mass spectrometry. The peptic peptide coverage maps are shown in Figure 19. 
Deuterium uptake curves were then generated for each peptic peptide, and are presented pairwise 
for the WT vs. A356N mutant (Figure 20A), WT vs. HAL9 (Figure 20B), and A356N vs. 
A356N-HAL9 (Figure 20C).  Overall, the rate of deuterium incorporation, and therefore protein 
dynamics, was the same for most of the peptides across all three comparisons during the time 
frame of the experiment (4 hours).  However, several important differences were observed that 
provide remarkable insight into the impact of the opposing effects of the A356N and HAL9 
substitutions on overall dynamics. 
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Figure 19: Amino acid sequences and peptic peptide coverage of all four c-ABL core proteins studied by HX 
MS.  The protein coverage maps were generated using the DynamX software package (Waters Corp.).  Amino acids 
not covered by pepsin digestion are indicated by the letter ‘X’.  The location of the A356N myristic acid binding 
pocket mutation as well as the region encompassing the modified HAL9 linker are outlined in red. 
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WT + HAL9Figure 20B
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A356N HAL9-A356NXFigure 20C
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Figure 20: Comparative deuterium uptake curves for peptic peptides derived from c-ABL core proteins.  
Deuterium uptake graphs were generated using the DynamX software package (Waters Corp.). The cumulative error 
of measuring deuterium uptake in these assays is approximately ± 0.20 Da.  Peptides displaying significant 
differences in deuterium uptake are outlined in orange. A, ABL-WT vs. A356N; B, WT vs. HAL9; C, A356N vs. 
HAL9-A356N. The sequence, numbering (ABL-1b) and mass of each peptide are shown. 
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Comparison of exchange in peptic peptides derived from WT ABL versus the active 
A356N mutant identified revealed nine peptides with more rapid deuterium uptake in the mutant, 
supporting the idea that disruption of the myristate binding pocket results in a more open, mobile 
structure. Most of the increases in deuterium incorporation observed in the A356N mutant 
localize to the N-lobe of the kinase domain (mapped to the structure of downregulated ABL in 
Figure 21). The peptide corresponding to ABL residues 282-293 (301-312 in ABL 1a 
numbering) not only showed more deuterium uptake in the A356N mutant, but the spectra 
indicate the presence of two populations of peptides, one of which is labeled more rapidly than 
the other (Figure 22). The half-life of conversion between the two populations in the mutant was 
around 10 minutes, whereas the conversion took much longer for the WT protein. These results 
indicate that the mutant was much more dynamic in this region and underwent partial unfolding 
of the EX1 type (Weis et al., 2006).  Analysis of exchange into four overlapping peptides in this 
region shows that just four amino acids (sequence Ile-Ile-Thr-Glu) are responsible for the altered 
dynamics of the A356N mutant. These residues are located in the tip of the two-strand β-hairpin 
pointing into the ATP-binding site, and include the gatekeeper threonine (Thr315; ABL-1a 
numbering).  Because this region is located at a great distance from the site of the activating 
mutation, these results support an allosteric connection between the myristic acid binding site in 
the C-lobe and part of the active site derived from the N-lobe.  These observations are consistent 
with previous HX MS studies in which GNF-2 binding to the myristic acid binding pocket in the 
C-lobe decreased deuterium uptake in the ATP binding site (Zhang et al., 2010; Iacob et al., 
2011). In addition to peptides derived from the N-lobe, peptide 432-446 (451-465 in ABL-1a) 
also displayed more deuterium uptake in A356N compared to WT. This peptide is located in the 
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α-helix adjacent to the site of the mutation in the kinase domain C-lobe, indicating that the 
A356N mutation also causes a local increase in solvent accessibility. 
Comparison of exchange between the WT and HAL9 forms of the c-ABL core revealed 
several regions with less deuterium uptake in HAL9, strengthening the idea that enhanced SH3 
interaction with the linker stabilizes the downregulated conformation of the kinase domain 
(Figures 20 and 21). The regions that showed reduced deuterium uptake in HAL9 included 
peptide 57-64 (76-83 in ABL-1a), which includes the N-terminal portion of the RT loop of the 
SH3 domain, SH2 domain peptide 115-125 (134-144 in ABL-1a), which is part of the α-helix 
that contacts the kinase domain C-lobe, and peptide 282-293 (ABL-1a 301-312) from the N-lobe 
of the kinase domain. The latter peptide overlaps with the same one that is more mobile in the 
A356N mutant as described above. Reduction of deuterium incorporation in these HAL9 regions 
supports the hypothesis that increasing SH3:linker interaction results in global stabilization of the 
inactive ABL core conformation. 
A final comparison of HX MS data from the active A356N mutant with A356N-HAL9 
showed that HAL9 substitution completely reverses the activating effects of A356N (Figures 21 
and 22).  Overall, the A356N-HAL9 protein had a very similar HX MS profile to that of HAL9 
alone, with reduced deuterium uptake in SH3 domain peptides 56-63 and 76-90 (ABL-1a 75-82 
and 95-109), and in the SH2 domain peptide 115-125 (ABL-1a 134-144) which contacts the 
kinase domain C-lobe. This peptide contains Tyr115 (ABL-1a Tyr158) which when mutated to 
aspartate increases ABL kinase activity (Figure 12). As discussed above, HAL9 substitution 
completely reversed kinase activation resulting from this SH2 domain mutation, consistent with 
global control of ABL kinase core conformation by SH3 interaction with the linker. 
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Figure 21: High-affinity linkers reduce hydrogen exchange in the c-ABL myristic acid binding pocket, the 
SH3 domain, and the kinase domain N-lobe. Regions of altered hydrogen exchange are indicated for the WT c-
ABL core vs. HAL9 (left), WT vs. the A356N myristic acid binding pocket mutant (middle) and HAL9 vs. HAL9-
A356N (right).  Differences in deuterium uptake are color-coded, with blue indicating peptides with a significant 
reduction in uptake between 0.7-1.0 Da and yellow indicating peptides that displayed subtle changes (less than 0.7 
Da difference between curves) in HAL9 vs. WT and in HAL9-A356N vs. A356N.  Magenta indicates peptides with 
more deuterium uptake (0.7-1.0 Da) in the A356N sample when compared with WT.  The cumulative error of 
measuring deuterium uptake in these assays is ± 0.20 Da. Proline residues that were introduced in HAL9 and HAL9-
A356N are colored orange and rendered as sticks. The A356N mutation is represented in blue sticks. The locations 
of the peptides are modeled on the structure of the myristoylated, downregulated c-ABL core (PDB entry 2F0O). 
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Figure 22: A kinase domain N-lobe peptide encompassing the gatekeeper residue is sensitive to A356N 
mutation in the myristate binding pocket.  (A) Mass spectra of deuterium incorporation into the ABL N-lobe 
peptide 282-293 were recorded over the time intervals shown. The start of the unfolding in this peptide from the 
A356N mutant is readily observed after 10 min. (B,C) Comparison of the deuterium uptake curves corresponding to 
four overlapping peptides across the 282-293 region identify a four amino acids peptide flanking the gatekeeper 
position (IITE) as responsible for the dynamic and conformational changes in A356N mutant. The position of this 
peptide in the crystal structure of the c-ABL core (PDB: 2FO0) is shown at the lower right. 
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2.4 DISCUSSION 
The discovery that the tyrosine kinase activity of BCR-ABL is the driving force behind CML led 
to the development of imatinib, a Type II ATP-competitive inhibitor of ABL as the first-line 
treatment for this rare form of leukemia (Druker, 2004).  Imatinib revolutionized CML therapy 
and laid the foundation for targeting kinase activity as a therapeutic approach to other forms of 
cancer.  However, despite the clinical success of imatinib, long term therapy often leads to the 
emergence of drug resistance and disease relapse (Nardi et al., 2004). Imatinib resistance results 
from kinase domain mutations that impact drug binding [e.g., gatekeeper T315I; (Gorre et al., 
2001)] or from mutations outside of kinase domain which induce an active site conformation 
incompatible with drug binding (Azam et al., 2003). The second-generation ATP- competitive 
ABL inhibitors nilotinib and dasatinib have been approved for therapy of imatinib-resistant CML 
(Rix et al., 2007). However, these drugs are also associated with resistance and do not overcome 
the T315I imatinib-resistance mutation. 
 The need to overcome the gatekeeper mutation and to target ABL kinase activity 
more specifically led to the discovery of allosteric kinase inhibitors. GNF-2, the prototype of this 
inhibitor family, targets the myristate binding pocket in the C-lobe to stabilize the inactive 
conformation of the kinase domain (Iacob et al., 2011; Zhang et al., 2010; Adrian et al., 2006). 
GNF-2 inhibits some imatinib-resistant forms of BCR-ABL, with T315I as a notable exception. 
This observation suggests that the T315I mutation uncouples the active site from allosteric 
control by myristate-binding pocket.  However, when combined with nilotinib or dasatinib, 
GNF-2 and related compounds overcome T315I mutations both in vitro and in vivo (Zhang et al., 
2010).  Combinations of GNF-2-type allosteric inhibitors and ATP competitive drugs also 
dramatically decrease the rate of experimental drug resistance, strongly suggesting that other 
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therapeutic approaches targeting natural mechanisms of kinase regulation may be of value in 
combating drug resistance. In this study, we focused on the potential of the SH3:linker 
interaction as an alternative allosteric regulator of kinase activity.  Our approach was inspired by 
mounting evidence that the ABL SH3 and SH2 domains maintain regulatory control over the 
ABL kinase domain even in the context of the active BCR-ABL kinase.  Indeed, imatinib 
resistance can arise from mutations in these regulatory domains as well as phosphorylation of the 
SH3 domain by Src-family kinases (Azam et al., 2003; Pene-Dumitrescu and Smithgall, 2010).  
Previous HX MS studies have shown that the ABL linker remains bound to the SH3 
domain even in the absence of kinase domain, supporting a prominent role for this interaction in 
ABL kinase regulation (Chen et al., 2008a). Our goal was to enhance SH3 interaction through 
systematic substitution of linker amino acid residues with proline without disturbing the overall 
structure of the downregulated c-ABL core. Using HXMS, we first showed enhanced SH3:linker 
engagement as a function of increased linker proline content in small proteins consisting of the 
NCap, SH3, SH2 and linker regions. Within the context of the larger ABL core protein, most of 
the HAL modifications maintained or reduced phosphorylation of key regulatory tyrosines 
relative to wild-type protein.  Among these, the HAL9 protein, with five additional linker 
prolines, showed the greatest enhancement of SH3:linker interaction without disturbing overall 
kinase regulation. 
The long-range allosteric influence of SH3:linker interaction on ABL kinase regulation 
became readily apparent when HAL9 was combined with mutations known to activate the c-
ABL core. Particularly striking was the observation that HAL9 substitution completely reversed 
the activating effect of the A356N mutation in the myristic acid binding pocket.  In contrast, 
HAL9 only partially reversed the activity of a non-myristoylated (G2A) ABL core protein, 
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suggesting that G2A and A356N produce distinct active conformations of the c-ABL core 
despite their functional relationship. In the case of the non-myristoylated ABL-G2A mutant, 
small-angle X-ray (Nagar et al., 2006) scattering supports a dramatic reorientation of the SH2 
domain onto the N-lobe of the kinase, where it stabilizes an active kinase domain conformation 
(Filippakopoulos et al., 2008). This active ‘top-hat’ conformation is also supported by previous 
HX MS studies of non-myristoylated ABL core proteins (Iacob et al., 2009).  On the other hand, 
HX MS of the ABL-A356N core protein presented here revealed no changes in deuterium 
incorporation at the SH2:C-lobe interface, the NCap or the SH2-kinase linker, indicating that 
ABL-A356N does not adopt the top hat conformation. These differences in active conformation 
help to explain why HAL9 completely reverses the activity of the A356N mutation.  In this case, 
the overall structure of the ABL core is likely to be maintained, with the SH3 domain bound to 
the linker and the myristoylated NCap bound to its C-lobe binding pocket.  Enhanced SH3:linker 
interaction via HAL9 substitution may compensate for allosteric uncoupling resulting from the 
A356N mutation. Indeed, HX MS studies showed that introduction of HAL9 decreased 
deuterium incorporation in the C-lobe at the site of the A356N mutation, the N-lobe adjacent to 
the active site as well as the SH3 and SH2 domains. These HX MS data also support an allosteric 
connection between the SH3 domain, the myristic acid binding pocket, and the active site. 
The allosteric impact of HAL9 was observed not only with the ABL kinase core protein 
but also within the context of full-length BCR-ABL.  Using human TF-1 myeloid cells 
transformed with BCR-ABL as a model system, we found that HAL9 substitution enhanced 
sensitivity to imatinib both in terms of BCR-ABL kinase activity and apoptosis. These data 
provide direct evidence that SH3:linker interaction maintains control over BCR-ABL kinase 
activity.  The enhancement in the apparent potency of imatinib against the HAL9 form of BCR-
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ABL most likely results from restructuring of the kinase domain in the downregulated 
conformation required for drug binding. 
In addition to imatinib, enhanced SH3:linker interaction dramatically sensitized BCR-
ABL-transformed TF-1 cells to the allosteric inhibitors GNF-2 and GNF-5, both in terms of 
kinase inhibition and the apoptotic response. These results support a three-way allosteric 
connection between the SH3 domain, the myristic acid binding pocket, and the active site.  This 
point is underscored by the observation that HAL9 substitution also sensitized the T315I mutant 
of BCR-ABL to GNF-2. 
In summary, our data show that the SH3:linker interface is a key node controlling the 
overall dynamics and regulation of the c-ABL kinase core, and that this regulatory influence is 
retained in the context of the BCR-ABL oncoprotein. Furthermore, the combination of HX MS, 
biochemical and biological studies strongly support allosteric interplay between the SH3:linker 
interface, the myristic acid binding pocket in the C-lobe, and the active site. Enhanced 
SH3:linker interaction sensitizes BCR-ABL to both Type II ATP competitive inhibitors such as 
imatinib as well as allosteric inhibitors targeting the C-lobe hydrophobic pocket. Our work 
strongly supports future drug discovery campaigns to identify small molecules that stabilize 
SH3:linker interaction as allosteric inhibitors of both wild-type and drug resistant forms of BCR-
ABL. 
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2.5 MATERIALS AND METHODS 
2.5.1 Cell culture 
The human GM-CSF-dependent myeloid leukemia cell line TF-1 was obtained from the 
American Type Culture Collection (ATCC) and maintained in RPMI 1640 supplemented with 
10% fetal bovine serum (FBS), 100 U/ml penicillin G, 100 µg/ml streptomycin sulfate, 0.25 
µg/ml amphotericin (Antibiotic-Antimycotic, Invitrogen) and 1 ng/ml human recombinant GM-
CSF. Sf9 insect cells were maintained in Grace’s medium (Gibco) supplemented with 10% FBS. 
293T cells were obtained from the ATCC and cultured in Dulbecco’s Modified Eagle’s medium 
(DMEM) containing 10% FBS and antibiotic-antimycotic. 
 
2.5.2 Expression and purification of ABL-SH3-SH2-HAL proteins 
The high affinity linker mutants HAL1 (K241P), HAL2 (V244P), HAL4 (T243P) and HAL5 
(G246P) were created by site-directed mutagenesis using the QuikChange method (Stratagene) 
and the pET-14b/SH32L plasmid as a template. This plasmid was previously used to express 
wild-type ABL SH3-SH2-linker (32L) protein for HXMS analysis (Chen et al., 2008a).The pET-
14b-HAL1 and HAL4 vectors were then used in subsequent round of mutagenesis to generate 
HAL3 (K241P, V244P) and HAL6 (T243P, G246P), respectively. The pET-14b-HAL3 vector 
was used to generate HAL7 (K241P, T243P, V244P) while the pET-14b-HAL7 vector was used 
to create HAL8 (K241P, T243P, V244P, G246P). The HAL8 construct was then used to create 
HAL9 (K241P, T243P, V244P, G246P, V247P) and subsequently HAL10 (K241P, T243P, 
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V244P, G246P, V247P, S248P).  All ABL 32L proteins were expressed in E. coli Rosetta2 
(Novagen) and purified using affinity chromatography with Ni-NTA agarose beads (Qiagen). 
Following cleavage of the hexahistidine tag at the N-terminus by human thrombin protease, the 
proteins were further purified by size exclusion chromatography. The theoretical mass for each 
protein matched the measured mass to within 0.5 Da by electrospray mass spectrometry (data not 
shown). 
2.5.3 Expression and purification of NCap-c-ABL core proteins 
The NCap-ABL core encompasses residues 1-531 of human c-ABL-1b with an internal deletion 
of residues 15-56 and a C-terminal cleavage site for the tobacco etch virus (TEV) protease 
followed by a hexahistidine tag. All ten HAL sequences were introduced into the NCap-ABL 
core using a two-step PCR-based strategy and the corresponding ABL SH3-SH2-HAL constructs 
as templates. The NCap-ABL core coding sequence with modified linkers were assembled in the 
cloning vector pSP72 (Promega) and subsequently subcloned into pCDNA3.1 (Invitrogen) for 
transient expression in 293T cells and pVL1392 (BD Biosciences) for expression in Sf9 insect 
cells. The pVL1392/NCap-ABL constructs were used to create high-titer recombinant 
baculovirus in Sf9 insect cells using linearized Baculogold DNA and the manufacturer’s protocol 
(BD Biosciences). For protein production, Sf9 cells were grown in monolayers on large plates 
and co-infected with NCap-Abl and YopH phosphatase baculoviruses.  YopH phosphatase 
promotes a downregulated conformation of NCap-Abl that allows high-yield purification from 
Sf9 cells. Sf9-cells were grown for an additional 72 h, harvested by centrifugation, and 
resuspended in 20 mM Tris-HCL (pH 8.3), 10% glycerol and 5 mM β-mercaptoethanol. Pellets 
were lysed by sonication and the lysates were clarified by centrifugation at 16,000 rpm for 30 
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min. The proteins were purified from the supernatant using a combination of ion exchange and 
affinity chromatography as described previously (Iacob et al., 2009). Upon purification, proteins 
were dialyzed against 20 mM Tris-HCl (pH 8.3) containing 100 mM NaCl and 3 mM DTT.  
 
2.5.4 Transient expression of c-ABL core proteins in 293T cells 
Human 293T cells (1 x 106) were plated in 60 mm dishes and incubated at 37 ºC overnight, 
followed by transfection with 2.5 µg plasmid DNA and X-tremeGENE9 DNA transfection 
reagent (Roche). Cells were lysed by sonication 24 h later in ice-cold RIPA buffer supplemented 
with protease and phosphatase inhibitors as described (Briggs and Smithgall, 1999). Cell lysates 
were clarified by centrifugation at 16,000 rpm for 10 min at 4 ºC and protein concentrations were 
determined using the Bradford Assay reagent (Pierce). Aliquots of total protein were heated 
directly in SDS sample buffer and separated by SDS-PAGE. For immunoprecipitation, protein 
concentrations were first normalized in lysis buffer, followed by addition of 1 µg of anti-His 
antibody (Abcam) and 20 µl of G-Sepharose (50% slurry; GE Healthcare). Following incubation 
at 4 ºC overnight, immunoprecipitates were washed three times in RIPA buffer and heated in 
SDS sample buffer. Following SDS-PAGE, proteins were transferred to nitrocellulose 
membranes (Bio Rad) for immunoblot analysis. Immunoreactive proteins were visualized and 
quantitated with appropriate infrared (IR) dye-labeled secondary antibodies using the Odyssey 
imaging system (LI-COR Biosciences). Antibodies used in this part of the study include ABL 
polyclonal (sc-131; Santa Cruz Biotechnology), ABL monoclonal (sc-23; Santa Cruz), phospho-
ABL (Tyr412, Tyr245, Tyr89; Cell Signaling Technology) and anti-phosphotyrosine (pY99; 
Santa Cruz). 
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2.5.5 Construction of Bcr-Abl HAL vectors and retroviral transduction of the 
human myeloid leukemia cell line, TF-1 
Oligonucleotides (648 bp) spanning the HAL9 and BCR-ABL kinase domain mutations E255V, 
Y253H and T315I plus flanking restriction sites were commercially synthesized (DNA 2.0). 
Each of these DNA fragments was then swapped for the corresponding region of wild-type BCR-
ABL and subcloned into the retroviral vector pMSCV-neo (Clontech). BCR-ABL kinase domain 
mutations were generated by site directed mutagenesis as described above. Following DNA 
sequence verification of all constructs, retroviral stocks were produced by co-transfection of 
293T cells with each pMSCV/Bcr-Abl plasmid and an amphotropic packaging vector as 
described previously (Meyn, III et al., 2006). TF-1 cells (1 X 106) were incubated with 5 ml of 
viral stock in the presence of 4 µg/ml Polybrene (Sigma-Aldrich) and centrifuged at 3000 rpm 
for 3 h at room temperature. Following infection, cells were washed, transferred to regular 
medium for 24 h and then put under G418 selection (800 µg/ml) for 14 days.  Following 
selection time, cells were maintained in medium supplemented with 400 µg/ml G418.  
 
2.5.6 Proliferation and apoptosis assays 
Proliferation of TF-1 cells was assayed in the absence of GM-CSF using the Cell Titer-Blue Cell 
Viability assay (Promega) according to the manufacturer’s protocol. Fluorescence intensity was 
then measured using a Gemini XS microplate spectrofluorimeter (Molecular Devices) at 544/590 
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nm excitation and emission wavelengths, respectively.  Caspase activation was measured using 
the Apo-One Caspase 3/7 assay (Promega) according to manufacturer’s protocol. Fluorescence 
intensity was measured on Gemini XS at 485/520 nm excitation and emission wavelengths, 
respectively.  
 
2.5.7 Hydrogen exchange experiments 
Hydrogen exchange experiments were performed essentially as described in Iacob et al (Iacob et 
al., 2009). Stock solutions of each ABL core protein (WT, HAL9, A356N, and A356N-HAL9) 
were prepared at 20 pmol/µL in 20 mM Tris-HCl (pH 7.96), 100 mM NaCl, 3 mM DTT in H2O. 
Deuterium exchange was initiated by dilution of each protein 15-fold with an identical buffer 
prepared in D2O at room temperature. At each deuterium exchange time point (ranging from 10 s 
to 4 h) an aliquot from the exchange reaction was removed and labeling was quenched by 
adjusting the pH to 2.5 with an equal volume of quench buffer (0.8 M guanidinium HCl, 0.8% 
formic acid) followed by freezing on dry ice.  Samples were stored at -80 °C prior to pepsin 
digestion and mass analysis.  
2.5.8 Mass analysis 
Each frozen sample was thawed rapidly and injected into a custom Waters nanoACQUITY 
UPLC HDX ManagerTM (Waters Corp., Milford, MA, USA) and analyzed as previously 
described (Wales et al., 2008). The protein samples were digested using a Poroszyme 
immobilized pepsin cartridge (Applied Biosystems) which was accommodated within the UPLC 
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system. The cooling chamber of the UPLC system which housed all the chromatographic 
elements was held at 0.1 °C for the entire analysis. The injected peptides were trapped and 
desalted for 3 min at 100 µL/min and then separated over 6 min with an 8%-40% 
acetonitrile:water gradient at 40 µL/min.  Chromatography was performed on a 1×100 mm 
Waters ACQUITY UPLC C18 BEH column containing 1.7 µm particles and the back pressure 
averaged 8800 psi at 0.1 °C. The average amount of back-exchange using this experimental setup 
was 18% to 25%, based on analysis of highly deuterated peptide standards. Deuterium levels 
were not corrected for back-exchange and are therefore reported as relative (Wales and Engen, 
2006). However, all comparisons were done under identical experimental conditions thus 
negating the need for back-exchange correction. The UPLC step was performed with protonated 
solvents, thereby allowing deuterium to be replaced with hydrogen from side chains and the 
amino/carboxyl termini which exchange much faster than amide linkages (Englander and 
Kallenbach, 1983). All experiments were performed in duplicate and the error of determining the 
deuterium levels was ± 0.20 Da in this experimental setup consistent with previously obtained 
values (Burkitt and O'Connor, 2008).   
Mass spectra were obtained with a Waters XEVO G2 TOF equipped with a standard ESI 
source. The instrument was configured as follows: capillary at 3.2 kV, trap collision energy at 6 
V, sampling cone at 35 V, source temperature of 80 °C and desolvation temperature of 175 °C. 
Mass spectra were acquired over an m/z range of 100 to 2000. Mass accuracy was ensured by 
calibration with 500 fmol/µL GFP, and was less than 10 ppm throughout all experiments. The 
mass spectra were processed with the software package DynamXTM (Waters) by centroiding an 
isotopic distribution corresponding to the +2, +3, or +4 charge state of each peptide. Deuteration 
levels were calculated by subtracting the centroid of the isotopic distribution for peptide ions of 
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undeuterated protein from the centroid of the isotopic distribution for peptide ions from the 
deuterium labeled sample. The resulting relative deuterium levels were automatically plotted 
versus the exchange-in time. Identification of the peptic fragments was accomplished through a 
combination of exact mass analysis and MSE (Plumb et al., 2006) using Identity Software 
(Waters). MSE was performed by a series of low-high collision energies ramping from 5–30 V, 
therefore ensuring proper fragmentation of all the peptic peptides eluting from the LC system. 
2.5.9 Data Visualization 
Peptic maps were obtained using the DynamX software package.  Local changes in isotope 
exchange were mapped to the crystal structure of c-Abl (PDB: 2F0O) using PyMOL (Seeliger 
and de Groot, 2010) 
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3.0  OVERCOMING IMATINIB RESISTANCE WITH SELECTIVE SRC-FAMILY 
KINASE INHIBITORS IN CHRONIC MYELOGENOUS LEUKEMIA 
3.1 ABSTRACT 
Src family kinases (SFKs) are important mediators of BCR-ABL signal transduction and 
oncogenesis in CML. BCR-ABL binds to and activates multiple SFKs in CML cells, including 
HCK and LYN. In turn, active SFKs directly phosphorylate regulatory tyrosine residues in the 
SH3 domain, the SH2-kinase linker, and the BCR-derived portion of BCR-ABL. Given the 
important role SFKs in BCR-ABL-mediated signaling and drug resistance, we studied the effect 
of the SFK-selective inhibitor A-419259 on human TF-1 myeloid cells transformed with 
clinically relevant imatinib-resistant forms of BCR-ABL (E255V, Y253H and T315I). 
Proliferation of TF-1 cells transformed with BCR-ABL E255V and Y253H was markedly 
inhibited by A-419249. The anti-proliferative effects of the inhibitor correlated with suppression 
of overall SFK activity. However, TF-1 cells transformed with the Bcr-Abl gatekeeper mutant 
T315I were completely cross-resistant to A-419259. Surprisingly, SFK activity in TF-1 cells 
expressing BCR-ABL T315I was not inhibited by this compound. Immunoprecipitation 
experiments show that endogenous LYN remained active in A-419259-treated TF-1 cells 
transformed with BCR-ABL T315I. These results suggest that in general, SFKs are important 
targets to overcome imatinib resistance in CML. However, our data also suggest a new 
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mechanism of BCR-ABL T315I-induced resistance to drugs that target SFKs in CML. We 
speculate that this effect may be due to an acquired ability of BCR-ABL T315I to phosphorylate 
SFKs at novel sites that interfere with drug action. 
3.2 INTRODUCTION 
 
CML results from the neoplastic transformation of a hematopoietic stem cell (Sawyers, 1992). 
CML was the first cancer in which a specific chromosomal abnormality was linked to the 
pathogenesis of the disease. This hallmark chromosomal abnormality is referred to as the 
Philadelphia chromosome (Ph) which results from the reciprocal translocation between the long 
arms of chromosomes 9 and 22 [t(9;22)(q34;q11)] (Rowley, 1973; Rowley, 1980). This 
translocation fuses the ABL and BCR loci, creating a hybrid BCR-ABL gene that is expressed as a 
chimeric BCR-ABL protein with deregulated tyrosine kinase activity (Shtivelman et al., 1985). 
Clinically, CML is characterized by a chronic phase defined by an increase in proliferation of the 
transformed progenitor cells that retain their ability to differentiate. Within 5-8 years of disease 
onset, CML progresses to the accelerated phase marked by decreased maturation of the myeloid 
and lymphoid compartments. The final blast crisis phase is characterized by the accumulation of 
immature blast cells that have lost the ability to differentiate. In about 80 percent of cases, CML 
blasts have a myeloblastic phenotype and the remaining 20 percent have a lymphoblastic 
phenotype. This phase of the disease resembles acute leukemias and is often fatal (Kurzrock et 
al., 1988; Advani and Pendergast, 2002; Ren, 2005). 
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Since BCR-ABL tyrosine kinase activity is required for the initiation and maintenance of 
CML, it represents an ideal therapeutic target. Imatinib (STI571; Gleevec) is a 2-
phenylaminopyrimidine inhibitor that targets the ATP binding site of the ABL kinase domain 
(Druker et al., 1996; Schindler et al., 2000). Treatment of CML with imatinib has been a 
remarkable clinical success, especially in the chronic phase of the disease. However, treatment 
failure in the blast crisis phase is often attributable to imatinib resistance caused by point 
mutations in the kinase domain of BCR-ABL(Azam et al., 2003). One of the most clinically 
challenging resistance mutations involves substitution of the ‘gatekeeper’ threonine with 
isoleucine (T315I) (Gorre et al., 2001; Shah et al., 2002). This threonine is located at the hinge 
region between the two lobes of the kinase domain and is termed the gatekeeper residue because 
it controls the access of inhibitors into a deep hydrophobic pocket near the active site (Nagar et 
al., 2002). A variety of small molecule kinase inhibitors that target the ATP binding site require 
threonine at this position for binding specificity. In the case of BCR-ABL, the hydroxyl group of 
threonine hydrogen bonds with imatinib as well as the second generation ATP competitive 
inhibitors nilotinib and dasatinib. Substitution of threonine with isoleucine results in the loss of 
this stabilizing hydrogen bond and steric hindrance between the bulky isoleucine side chain and 
the drugs thus prevents access to the hydrophobic pocket. 
In addition to kinase domain mutations, a growing body of evidence suggests that SFKs 
play a clinically important role in BCR-ABL signal transduction and imatinib resistance as well. 
The first evidence linking BCR-ABL and SFKs in CML was shown by Danhauser-Riedl’s group 
(Danhauser-Riedl et al., 1996). In this study, BCR-ABL associated with and increased the kinase 
activity of HCK and LYN in murine 32D cells transformed with BCR-ABL and in CML cell 
lines such as BV173, LAMA-84 and K562. The interaction between BCR-ABL and HCK is 
 113 
mediated by SH3, SH2, kinase domain and C-terminal domains of BCR-ABL as well as SH3 and 
SH2 domains of HCK (Stanglmaier et al., 2003b; Lionberger et al., 2000).  
Subsequent work has implicated SFKs in the phosphorylation of BCR-ABL on tyrosine 
sites that affect its regulation and oncogenicity. For example, Tyr177 in the BCR portion of the 
protein is phosphorylated by HCK and LYN, resulting in the recruitment and binding of the 
GRB2/SOS complex and subsequent activation of RAS/ERK signaling downstream (Warmuth et 
al., 1997; Meyn, III et al., 2006). In addition, kinase-dead HCK suppresses STAT5 activation 
and blocks BCR-ABL-induced transformation of myeloid cells, suggesting that HCK is a key 
intermediate linking BCR-ABL with this survival signaling pathway (Klejman et al., 2002; 
Lionberger et al., 2000). HCK, LYN and FYN directly phosphorylate tyrosine residues in the 
SH3 and SH2 domains as well as the SH2-kinase linker of BCR-ABL that have been implicated 
in the regulation of BCR-ABL kinase activity (Meyn, III et al., 2006). Substitution of these 
residues with phenylalanine impaired BCR-ABL-mediated transformation of myeloid progenitor 
cells to cytokine independence, suggesting an important function for SFK-mediated 
phosphorylation of BCR-ABL in vivo.  
Previous work from our laboratory showed that A-419259, a SFK-selective inhibitor, 
blocks CML cell proliferation specifically in Ph+ cell lines and inhibited Erk and Stat5 activation 
(Lionberger et al., 2000; Wilson et al., 2002). This study suggested that BCR-ABL-mediated 
transformation of myeloid cells is dependent on SFK activity. More recent work from our 
laboratory showed that A-419259 induces growth arrest and apoptosis in CD34+ cells isolated 
from CML patients. In addition, expression of a form of HCK with engineered resistance to A-
419259 protected CML cells from the antiapoptotic and antiproliferative effects of this SFK 
inhibitor. Furthermore, overexpression of HCK in CML cells induced resistance to imatinib and 
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sensitivity was restored upon inhibition of HCK kinase activity (Pene-Dumitrescu et al., 2008; 
Pene-Dumitrescu and Smithgall, 2010).  
The literature discussed above supports an important role for SFKs in the pathogenesis of 
CML and drug resistance. In this study we investigated whether the SFK inhibitor A-419259 is 
effective against human myeloid cells transformed with three common imatinib-resistant forms 
of BCR-ABL (E255V, Y253H and T315I). We found that imatinib resistance due to mutations in 
the P-loop (E255V and Y253H) can be completely overcome with this inhibitor. However, cells 
transformed with the gatekeeper mutant, T315I, were completely resistant to the anti-
proliferative effects of A-419259.  Moreover, A-419259 treatment failed to inhibit SFKs in cells 
transformed with BCR-ABL T315I.  The same cross-resistance phenomenon was observed upon 
expression of wild-type HCK in cells transformed with T315I BCR-ABL. A final series of 
experiments demonstrates that BCR-ABL T315I phosphorylates HCK much more aggressively 
than wild-type HCK in a defined system, suggesting that enhanced phosphorylation of HCK may 
be responsible for A-419259 resistance in BCR-ABL T315I-transformed cells. Our data also 
highlight the importance of SFKs in imatinib resistance, their importance as therapeutic targets 
and a possible new mechanism of resistance involving the gatekeeper mutation. 
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3.3 RESULTS 
 
3.3.1 Transformation of TF-1 cells with imatinib-resistant BCR-ABL mutants 
As a model system for the present study, we chose the human myeloid leukemia cell line, TF-1.  
Like normal myeloid progenitors, TF-1 cells require GM-CSF, IL-3 or other cytokines for 
growth and survival in culture.  Our previous studies have shown that TF-1 cells are transformed 
into a cytokine-independent phenotype following retroviral transduction with wild-type BCR-
ABL (Meyn, III et al., 2006). We transformed TF-1 cells with wild-type BCR-ABL as well as 
three imatinib-resistant BCR-ABL mutants that commonly arise in patients.  These include the 
gatekeeper mutant, T315I, as well as two additional mutants that localize to the phosphate-
binding ‘P-loop’ of the kinase domain active site (E255V, Y253H; Figure 23). To confirm the 
drug-resistant phenotype, we performed cell proliferation assays in the absence of GM-CSF and 
with increasing concentrations of imatinib over 72 hours (see Materials and Methods). As 
expected, proliferation of TF-1 cells expressing wild-type BCR-ABL was blocked by imatinib at 
1 µM (Figure 24).  In contrast, all three TF-1 cell populations transduced with the imatinib-
resistant forms of BCR-ABL grew at the same rate in the presence of imatinib at the highest 
concentration tested (1 µM).   
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Figure 23: Imatinib resistant mutations. A, structure of ABL kinase domain with imatinib (PDB code 1IEP). The 
side chain of gatekeeper residue Thr315 is highlighted in green, side chain of Y253 is in pink and side chain of E255 
is in orange. These three residues and imatinib are shown in the boxed area. B, close-up view of the three amino 
acids and their relationship with imatinib. C, close-up view of the boxed area with three mutants T315I, Y253H, 
E255V. This close-up view shows the steric clash of the isoleucine side chain at the gatekeeper residue and the loss 
of aromatic interaction at the Y253H residue.  
 117 
WT E255V
C
el
l N
um
be
r
(F
ol
d 
C
ha
ng
e 
O
ve
r 
C
on
tr
ol
)
Imatinib, µM
Y253H T315I
Time, hr
0 20 40 60 80
0
1
2
3
4
5
Time, hr
0 20 40 60 80
0
1
2
3
4
5
Time, hr
0 20 40 60 80
0
2
4
6
Time, hr
0 20 40 60 80
0
1
2
3
4 0 µM
0.1 µM
0.3 µM
1.0 µM
 
 
Figure 24: Effect of imatinib on TF-1 cells expressing wild-type and imatinib- resistant BCR-ABL mutants.  
Human TF-1 myeloid cells were transduced with wild-type (WT) BCR-ABL as well as imatinib resistant mutant 
E255V, Y253H, and T315I retroviruses. Transformed cells were plated in triplicate wells in the presence of the 
indicated concentrations of imatinib. Cell viability was measured at the indicated time points using Cell Titer Blue 
assay. Data are expressed as cell number fold change +/- SD. 
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3.3.2 Imatinib resistance due to kinase domain mutations E255V and Y253H but 
not T315I are overcome with the selective Src family kinase inhibitor, A-419259 
We next investigated the sensitivity of the same panel of TF-1 cells to the effects of the SFK 
inhibitor, A-419259. Cell proliferation was inhibited in TF-1 cells expressing wild-type BCR-
ABL in response to increasing concentrations of A-419259 over 72 hours (Figure 25), consistent 
with our previous reports (Wilson et al., 2002). Interestingly, cells expressing BCR-ABL 
imatinib resistant mutants E255V and Y253H also displayed growth arrest in response to A-
419259 treatment. Cells expressing the E255V and Y253H mutant responded in a similar way to 
cells expressing wild-type BCR-ABL, and proliferation was almost completely blocked at a 
concentration of 1µM. However, TF-1 cells expressing the T315I mutant were completely 
resistant to the effects of A-419259 in terms of cell proliferation. 
We next investigated the effects of A-419259 treatment on SFK and BCR-ABL protein-
tyrosine phosphorylation in whole cell lysates by immunoblot analysis. SFK phosphorylation 
was assayed with a phosphospecific antibody directed against the activation loop 
phosphotyrosine (pY418), which correlates with kinase activity.  Because BCR-ABL is 
phosphorylated on multiple tyrosines, phosphorylation was evaluated as overall phosphotyrosine 
content. As shown in Figure 26, in TF-1 cells transformed with wild-type, Y253H, and E255V 
BCR-ABL, endogenous SFK autophosphorylation was inhibited in a concentration-dependent 
manner.  BCR-ABL phosphotyrosine content was also inhibited in these cells at higher A-
419259 concentrations, consistent with our previous observations that SFKs phosphorylate BCR-
ABL on multiple tyrosine residues both in vitro and in vivo (Meyn, III et al., 2006). These 
observations are consistent with the effect of A-419259 treatment on the proliferation of these 
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cell lines.  In contrast,  A-419259 treatment had no effect on SFK activation loop 
phosphorylation or BCR-ABL phosphotyrosine content in TF-1 cells expressing BCR-ABL 
T315I, suggesting that T315I confers cross-resistance to this SFK inhibitor.  
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Figure 25: Sensitivity of TF-1 cells expressing wild-type and imatinib-resistant forms of BCR-ABL to the Src 
family kinase inhibitor A-419259.  TF-1 cells were cultured in the presence of A-419259 at concentrations shown. 
Viable cells were assayed in triplicate using the cell Titer Blue assay at the indicated time points. Data are expressed 
as relative cell number +/- SD. 
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Figure 26: TF-1 cells expressing Bcr-Abl T315I are insensitive to the effects of SFK inhibitor A-419259.  TF-1 
cells expressing wild-type Bcr-Abl or imatinib-resistant mutants were treated with increasing concentrations of A-
419259 for 16 h. Clarified cell lysates were assayed by immunoblotting analysis for expression of Bcr-Abl protein, 
Bcr-Abl phosphotyrosine content (pAbl), autophosphorylated SFKs (pSFK) and actin as a loading control. 
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3.3.3 The myeloid SFKs LYN and HCK acquire resistance to A-419259 in TF-1 
cells transformed by BCR-ABL T315I  
We first investigated whether the myeloid SFK LYN specifically showed resistance to A-419259 
in BCR-ABL-T315I transformed TF-1 cells.  LYN is strongly expressed in this cell line where it 
appears as a doublet due to expression of the LYN-A and LYN-B isoforms. Following treatment 
of TF-1 cells expressing BCR-ABL wild-type, E255V, Y253H or T315I with 1 µM A-419259, 
we immunoprecipitated LYN and analyzed its inhibitor responsiveness using the antibody to the 
activation loop phosphotyrosine residue (Figure 27A). In TF-1 cells expressing wild-type BCR-
ABL, LYN activation loop phosphorylation was completely blocked by A-419259 treatment. 
Similar results were obtained with cells expressing BCR-ABL E255V and Y253H, with LYN 
activation loop phosphorylation dramatically decreased but not completely suppressed as in 
treated cells expressing wild-type BCR-ABL. In striking contrast, LYN activation loop 
phosphorylation was unaffected by A-419259 treatment in cells transformed with the BCR-ABL 
T315I mutant.  
To determine whether A-419259 cross-resistance is specific to LYN or if it could be 
observed with other Src-family members linked to BCR-ABL, we overexpressed HCK in TF-1 
cells transformed with the wild-type and T315I forms of BCR-ABL. Phosphorylation of HCK at 
the activation loop tyrosine was almost completely inhibited by 1 µM A-419259 in cells 
expressing wild-type BCR-ABL, similar to the effects observed with endogenous LYN. 
However, HCK activation loop phosphorylation was resistant to the effects of A-419259 in cells 
expressing BCR-ABL T315I (Figure 27B).  
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Figure 27: Endogenous LYN and exogenous HCK are cross-resistant to the SFK inhibitor A-419259 in cells 
expressing BCR-ABL T315I.  A) TF-1 cells expressing wild-type (WT) and imatinib-resistant BCR-ABL (E255V, 
Y253H, T315I) were grown overnight in the presence of 1 µM A-419259. Endogenous LYN was 
immunoprecipitated from clarified lysates and analyzed by immunoblotting with antibodies to LYN protein and to 
the phosphorylated activation loop (pLYN). LYN is expressed as two isoforms from two separate loci, LYN-A and 
LYN-B.  B) TF-1 cells expressing BCR-ABL wild-type and T315I were transduced with HCK retrovirus. TF-1 cells 
expressing both BCR-ABL and HCK were treated with 1 µM A-419259 for 16 h. HCK was immunoprecipitated 
from clarified extracts and analyzed by immunoblotting with antibodies to HCK as well as its phosphorylated 
activation loop (pHCK). 
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3.3.4 HCK is a direct substrate for the ABL kinase  
Results presented in the preceding sections show that SFKs become resistant to the effects of A-
419259 in cells transformed with the BCR-ABL imatinib-resistant mutant, T315I.  Previous 
studies have shown that this gatekeeper mutation alters the catalytic properties of the ABL kinase 
domain, resulting in enhanced kinase activity (Iacob et al., 2009; Azam et al., 2008). These 
findings suggest a mechanism of cross-resistance in which BCR-ABL T315I directly 
phosphorylates HCK or LYN, thereby affecting inhibitor action. To investigate this possibility 
without interference from endogenous mammalian cell kinases, we turned to Sf9 insect cells.  
Here we expressed kinase-dead HCK either alone or together with wild-type or T315I ABL 
kinase core proteins, and analyzed the extent of HCK phosphorylation by immunoblotting with 
the activation loop phosphospecifc antibody.  As shown in Figure 28, kinase-dead HCK was 
phosphorylated by both ABL proteins, but the extent of phosphorylation was dramatically higher 
upon co-expression of HCK with ABL T315I compared to wild-type ABL. This is the first 
evidence to demonstrate that SFKs can be directly phosphorylated by ABL kinase. These data 
support a previously unrecognized consequence of the BCR-ABL T315I mutation in terms of 
SFK phosphorylation, which may account in part for the observed cross-resistance to A-419259. 
 124 
W
T
T3
15
I
H
ck
K
D
W
T:
H
ck
K
D
 1
:1
W
T:
H
ck
K
D
 2
:1
T3
15
I:H
ck
 K
D
 1
:1
T3
15
I:H
ck
 K
D
 2
:1
Hck
Abl
Actin
pHck
 
 
Figure 28: Kinase-dead HCK is phosphorylated by wild-type and T315I ABL in Sf9 insect cells.  Sf9 insect 
cells were infected with wild-type and T315I c-ABL core baculoviruses either alone or co-infected with kinase dead 
HCK (HCK KD) baculovirus at a 1:1 (WT/TI: HCK KD) or 2:1 (WT/TI:HCK KD) virus ratio. Following 24 h 
infection, clarified lysates were analyzed by immunoblotting with antibodies to the phosphorylated activation loop 
(pHCK), HCK, ABL and actin as loading control. 
 
 125 
3.4 DISCUSSION 
To date, there is strong evidence supporting the crucial role of Src-family kinases in many 
aspects of CML pathogenesis (Li, 2008). Cross-talk between SFKs and BCR-ABL promotes 
oncogenic signaling downstream (Danhauser-Riedl et al., 1996; Lionberger et al., 2000; 
Warmuth et al., 1997; Klejman et al., 2002). SFKs interact with and phosphorylate BCR-ABL 
leading to recruitment of adaptor proteins to BCR-ABL and subsequent activation of 
downstream signaling. Phosphorylation of BCR-ABL by SFKs also interferes with regulation of 
the kinase domain and desensitization to targeted therapies (Warmuth et al., 1997; Meyn, III et 
al., 2006). In turn BCR-ABL induces expression and activation of SFKs that play important roles 
in the progression of the disease to blast crisis. SFKs also contribute to clinical CML drug 
resistance in the absence of BCR-ABL kinase domain mutations. For example, work from our 
group has shown that over-expression of HCK is sufficient to induce imatinib resistance in CML 
cell lines (Pene-Dumitrescu and Smithgall, 2010).  Similarly, elevated LYN expression and 
activity have been observed in samples from patients after imatinib and nilotinib therapy failure 
and in the absence of BCR-ABL kinase domain mutations (Okabe et al., 2011; Ptasznik et al., 
2004; Gioia et al., 2011).  Based on these data, SFKs represent an important therapeutic target in 
CML. 
Previous work from our group has shown that global inhibition of SFK activity with the 
ATP-competitive pyrrolo-pyrimidine A-419259 leads to growth arrest and apoptosis in CML cell 
lines and in primary CD34+ CML cells (Lionberger et al., 2000; Wilson et al., 2002; Pene-
Dumitrescu et al., 2008). In addition, expression of an HCK mutant with engineered resistance to 
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A-419259 protects CML cells against the antiproliferative and apoptotic effects of this 
compound, providing important evidence that SFKs are the primary target for this inhibitor in 
CML cells (Pene-Dumitrescu and Smithgall, 2010). In the present study, we extended our 
investigation of A-419259 to human TF-1 myeloid cells transformed with clinically relevant 
imatinib-resistant forms of BCR-ABL (E255V, Y253H and T315I). Proliferation of TF-1 cells 
transformed with BCR-ABL E255V and Y253H was markedly inhibited by A-419249. The anti-
proliferative effects of the inhibitor correlated with suppression of overall SFK activity and a 
reduction on BCR-ABL phosphotyrosine content. However, TF-1 cells transformed with the 
BCR-ABL gatekeeper mutant T315I were completely cross-resistant to A-419259. Surprisingly, 
endogenous SFKs present in the T315I-transformed cells were not inhibited by this compound. 
Immunoprecipitation experiments identified LYN as an endogenous myeloid SFK resistant to A-
419259 in TF-1 cells expressing Bcr-Abl T315I. We also showed that the same mechanism of 
resistance occurred upon over-expression of HCK in the TF-1/BCR-ABL-T315I cells. 
These observations suggest a cross-resistance mechanism in which BCR-ABLT315I 
acquires the ability to phosphorylate SFKs and induce drug-resistance.  In support of this 
mechanism, we showed that kinase-dead HCK was strongly phosphorylated by an ABLT315I 
core protein in insect cells, while wild-type ABL was less effective at doing so. This observation 
is consistent with recent reports that gatekeeper mutations alter the kinetic, dynamic and 
signaling properties of both ABL and BCR-ABL kinases.  Future studies will determine whether 
BCR-ABLT315I-mediated resistance of HCK, LYN or other SFKs to A-419259 is due to 
differences in the extent of HCK phosphorylation, differential phosphorylation at drug-sensitive 
sites, or both. Alternatively, T315I mutation may enhance the expression of P-glycoprotein 
(Pgp), the ATP-dependent xenobiotic transport protein associated with the multi-drug resistant 
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phenotype. Future studies will investigate the role of Pgp expression as a possible mechanism 
conferring cross-resistance to A-419259. 
 
In summary, data presented here suggest that selective inhibitors of SFKs may have 
translational use in the treatment of some types of imatinib-resistant CML, including cases with 
kinase domain mutations other than T315I or where SFKs such as HCK and LYN are over-
expressed. However our data also revealed a new mechanism of BCR-ABL T315I-induced 
resistance to drugs that target SFKs in addition to BCR-ABL, and may help to explain why drug 
resistant CML linked to the BCR-ABL T315I mutation is so difficult to manage, even with 
broader spectrum inhibitors such as dasatinib which target both BCR-ABL and SFKs.  
3.5 MATERIALS AND METHODS 
3.5.1 Cell Culture 
The human GM-CSF-dependent myeloid leukemia cell line TF-1 was obtained from the 
American Type Culture Collection (ATCC) and maintained in RPMI 1640 supplemented with 
10% fetal bovine serum (FBS), 100 U/ml penicillin G, 100 µg/ml streptomycin sulfate, 0.25 
µg/ml amphotericin (Antibiotic-Antimycotic, Invitrogen) and 1 ng/ml human recombinant GM-
CSF. Sf9 insect cells were maintained in Grace’s medium (Gibco) supplemented with 10% FBS. 
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3.5.2 Mutagenesis of the ABL kinase domain and transformation of TF-1 cells 
with BCR-ABL retroviruses 
Imatinib-resistant BCR-ABL kinase domain mutants E255V, Y253H and T315I were created by 
site-directed mutagenesis of a wild-type p210 BCR-ABL cDNA as described elsewhere (O’Hare 
T). The nucleotide sequences of the mutant cDNAs were confirmed by automated DNA 
sequence analysis. Wild-type and imatinib-resistant mutant forms of Bcr-Abl were subcloned 
into the retroviral vector pMSCV-neo (Clontech). 
To make retroviral stocks, 293T cells were co-transfected with each retroviral construct 
and an amphotropic packaging vector as described (Briggs SD). TF-1 cells (106) were incubated 
with 5 ml of viral supernatant in the presence of 4 µg/ml polybrene and centrifuged at 2400 rpm 
for 3 h at room temperature to enhance infection. Cell populations were selected with 800 μg/ml 
G418 for 10-14 days. Following selection, cells were maintained in medium supplemented with 
400 µg/ml G418.  
 
3.5.3 Cell proliferation assays 
Proliferation of Bcr-Abl-transformed TF-1 cells was assayed in the absence of GM-CSF using 
the CellTiter-Blue Cell Viability assay (Promega) according to the manufacturer’s protocol. 
Cells were plated in triplicate and incubated with increasing concentrations of imatinib, A-
419259 or DMSO for up to 72 hours. Fluorescence intensity was measured using a Gemini XS 
microplate spectrofluorimeter (Molecular Devices) at 544/590 nm excitation and emission 
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wavelengths, respectively.  All experiments were performed in triplicate and data are presented 
as the mean +/- SD for each timepoint. 
3.5.4 Immunoblotting and Immunoprecipitation 
To analyze protein expression and tyrosine phosphorylation, TF-1 cells expressing different 
BCR-ABL mutants were treated with the indicated concentration of A-419259 for 16 hours. 
Cells were collected by centrifugation, washed with PBS and lysed by sonication in ice-cold 
RIPA buffer supplemented with protease and phosphatase inhibitors as described. Cell lysates 
were clarified by centrifugation at 16,000 rpm for 10 min at 4 ºC and protein concentrations were 
determined using the Bradford Assay reagent (Pierce). Aliquots of total protein were heated 
directly in SDS sample buffer and separated by SDS-PAGE. For immunoprecipitation of LYN or 
HCK, protein concentrations were first normalized in lysis buffer, followed by addition of 1 µg 
of anti-LYN or anti-HCK antibodies. Following SDS-PAGE, proteins were transferred to 
nitrocellulose membranes (BioRad) for immunoblot analysis. Immunoreactive proteins were 
visualized and quantitated with appropriate infrared (IR) dye-labeled secondary antibodies using 
the Odyssey imaging system (LI-COR Biosciences). Antibodies used in this part of the study 
include ABL polyclonal (sc-131; Santa Cruz Biotechnology), Abl monoclonal (sc-23; Santa 
Cruz), phospho-Abl (Tyr412; Cell Signaling Technology), anti-phosphotyrosine (pY99; Santa 
Cruz), actin (source), phospho-Src (Tyr418; source). 
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3.5.5 Retroviral transduction of TF-1 cells 
Wild-type Hck was subcloned into the retroviral expression vector pMSCV-puro. Retroviral 
stocks were produced from the resulting construct in 293T cells using an amphotropic packaging 
vector as described above. TF-1 cells expressing wild-type and T315I BCR-ABL mutant were 
plated in 6 well plates at 1X 106 cells/well in 5 ml of viral supernatant in the presence of 4 µg/ml 
Polybrene (hexadimethrine bromide) and centrifuged at 2400 rpm for 3 hours at room 
temperature. After infection cells were placed under puromycin selection (1µg/ml) for 10 days. 
After the selection time, cells were maintained in medium with G418 (400 µg/ml) and 
puromycin (0.5 µg/ml). The protein expression and phosphorylation status of HCK was 
determined by immunoprecipitation as described in the above section. 
3.5.6 Expression in Sf9 insect cells 
Using site directed mutagenesis, the Lys269 to Asp (K269D) mutation was introduced into the 
coding sequence of human HCK (QuickChange XL Site-directed Mutagenesis Kit, Stratagene). 
The NCap-c-ABL wild-type and T315I constructs encompass residues 1-531 of human c-ABL-
1b with residues 15-56 deleted and containing c-terminal tobacco etch virus (TEV) protease 
cleavage site followed by hexahistidine tag. HCK-KD and the NCap-c-ABL constructs were 
cloned into pVL1392 (BD biosciences) and each plasmid was used to create high-titer 
recombinant baculovirus in Sf9 insect cells using Baculogold DNA and the manufacturer’s 
protocol (BD Biosciences). To determine activation loop phosphorylation of HCK, 2.5 X 106 Sf9 
cells were plated in 60 mm dishes in Grace’s medium supplemented with 10% FBS. Cells were 
then infected with wild-type and T315I c-ABL core viruses alone or co-infected with kinase dead 
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HCK virus at 1:1 or 2:1 (ABL/HCK) ratio. Twenty-four hours later, clarified cell lysates were 
analyzed by immunoblotting with antibodies to the phosphorylated activation loop of HCK 
(pY418), HCK, ABL and actin. 
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4.0   OVERALL DISCUSSION 
4.1 SUMMARY OF FINDINGS AND SIGNIFICANCE 
 
Despite the unprecedented response rates with imatinib, resistance to imatinib has been 
inevitable (Roychowdhury and Talpaz, 2011). Based on extensive work on imatinib-induced 
resistance, it is evident that resistance mechanisms can be BCR-ABL-dependent or independent. 
Fifty percent of the BCR-ABL dependent mechanisms of resistance relate to kinase domain 
mutations. To date more than 100 kinase mutations have been identified that map not only onto 
the drug binding site but also on other regions of the protein (Quintas-Cardama et al., 2009). The 
mutations arising in the SH3, SH2, SH2-Kinase linker, SH3-SH2 connector and the kinase 
domains induce allosteric conformational changes that interfere with drug binding (Azam et al., 
2003; Shah et al., 2002; Sherbenou et al., 2010). These studies paved the way to the design of 
second generation tyrosine kinase inhibitors either with more potency than imatinib (nilotinib) or 
drugs that also target the active conformation of the protein (dasatinib). However, the second 
generation drugs cannot overcome the most recalcitrant gatekeeper mutations and also lead to 
resistance. A third generation of tyrosine kinase inhibitor in clinical trials, ponatinib, binds to the 
ATP binding site of the inactive conformation of the protein and accommodates the isoleucine 
side chain of the gatekeeper mutant T315I (Ohanian et al., 2012; Zhou et al., 2011). 
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Prior to this study, the use of allosteric inhibitors that target BCR-ABL kinase at a 
distance from the active site has gained a lot of attention as an alternative strategy to overcome 
resistance (Zhang et al., 2009). One such example is GNF-2, which targets the C-lobe myristic 
acid binding pocket of the ABL protein (Adrian et al., 2006). This compound and its analogs 
have shown inhibitory effects on most BCR-ABL mutants with the notable exception of the 
T315I mutation. This observation suggests that T315I uncouples the active site from allosteric 
control by the myristate binding pocket in the C-lobe. However, when combined with nilotinib or 
dasatinib, GNF-2 and related compounds overcome T315I mutations. 
Recently work from our group has shown that phosphorylation of BCR-ABL on Tyr89 in 
the SH3 domain causes imatinib resistance. Furthermore, dynamics analyses revealed that 
phosphorylation of this residue disrupts intramolecular SH3:linker binding, an interaction 
necessary for negative regulation of c-ABL kinase activity (Chen et al., 2008b; Meyn, III et al., 
2006; Pene-Dumitrescu and Smithgall, 2010). These studies support the idea that mutations 
occurring outside the active site allosterically induce an active conformation of the kinase 
domain which is less compatible with imatinib binding. Also, these studies suggest that the SH3 
domain may have a regulatory effect in the context of active BCR-ABL kinase. Therefore, in the 
first aim of my thesis, I attempted to determine the role of SH3:linker interaction as an alternate 
allosteric regulator involved in stabilizing a single conformation of the kinase domain and its 
impact in sensitizing the kinase to currently established inhibitors. 
In addition, to date, there is a wealth of literature supporting the crucial role of SFKs in 
many aspects of CML pathogenesis and BCR-ABL-independent mechanisms of resistance 
(Ptasznik et al., 2004) .Based on these observations, SFKs represent important therapeutic targets 
in CML. Therefore, in the second aim of my thesis, I sought to understand the effect of global 
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inhibition of SFK activity with Src-selective inhibitor A-419259 in clinically relevant imatinib 
resistant BCR-ABL mutants. 
 
4.1.1 SH3:linker interaction as an allosteric regulator of ABL and BCR-ABL 
kinases 
To understand the contribution of the SH3:linker interaction in allosteric regulation of ABL and 
BCR-ABL kinases, we worked with our collaborators to strengthen this interaction by the 
sequential substitution of linker residues with proline, and referred to these modifications as 
High Affinity Linkers (HAL). This approach was used previously by our group to strengthen the 
SH3:linker interaction in HCK (Lerner et al., 2005). However, unlike in HCK where substitution 
of two lysine residues tightened the SH3:linker interaction, substitution of at least 4 residues 
(HAL8) in ABL linker was necessary to tighten this interaction in small ABL proteins comprised 
of the NCap, SH3, SH2 and the linker regions. The increase in proline content correlated with an 
increase in the affinity of the SH3 for the linker as seen by HX MS. Next, I introduced these 
substitutions in the core of ABL (NCap-SH3-SH2-Linker-Kinase domain) and expressed the 
resulting proteins in 293T cells. Within the context of the larger protein, HAL9 (5 prolines) 
enhanced the SH3:linker interaction without disturbing overall kinase regulation as determined 
by the comparative phosphorylation of key tyrosines relative to the wild-type kinase core. To 
understand the long-range allosteric impact of enhanced SH3:linker interaction in the context of 
mutations that activate the kinase, I combined HAL9 and the activating mutations A356N, G2A , 
T315I, Y158D and determined the extent of reversal of activation. The A356N and G2A 
mutations are functionally similar in that they exclude the NCap from the myristic acid binding 
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pocket by inhibiting binding (A356N) or by inhibiting myristoylation of the Ncap (G2A). 
Enhancement of SH3:linker interaction, completely reversed the activating effects of A356N 
mutation while partially reversing activating effects of non-myristoylated G2A mutation. These 
observations suggest that these two proteins have distinct active conformations. In the case of 
G2A, previous small-angle X-ray scattering and HX MS studies support a “top hat” 
conformation for the non-myristoylated ABL core protein in which the SH2 domain is reoriented 
to interact with the N-lobe of the kinase (Nagar et al., 2006; Filippakopoulos et al., 2008; Iacob 
et al., 2009). Though in the SAXS study the locations of the SH3 and the linker domains were 
not determined, in such a highly reoriented conformation HAL9 might not compensate for the 
activating effects of G2A. However, our HX MS results in this study indicate that A356N 
mutation does not lead to the “top hat” conformation because there were no changes in 
deuterium incorporation in ABL-A356N at the SH2:C-lobe interface, the NCap or the linker 
regions. The dynamic and conformational changes of ABL-A356N are represented by increases 
in deuterium incorporation at the site of A356N mutation and in a peptide encompassing the 
gatekeeper residue in the N-lobe. Interestingly, these changes are completely reversed by HAL9 
substitution.  Thus, the extent to which HAL9 compensates for the activating effects of mutations 
is dependent on differences in active conformations of the ABL core protein. 
In the context of the ABL gatekeeper mutation (T315I), we have previously shown that 
this mutation induces local conformational changes at the site of the mutation and in the SH3 
domain in the myristoylated core of the protein (Iacob et al., 2009). Also, T315I is shown to 
uncouple the active site from allosteric regulation by the myristic acid binding site inhibitors. 
Interestingly, in this study I show that HAL9 partially reverses the activating effects of T315I. 
Furthermore, HAL9 also reverses the activating effects of Y158D mutation that occurs at the 
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SH2:kinase interface. This suggests that SH3:linker interaction can allosterically regulate  SH2 
and C-lobe kinase domains. 
To understand the allosteric regulation by HAL9 in the context of full length BCR-ABL, 
I introduced wild-type and HAL9-BCR-ABL in TF-1 cells. HAL9 sensitized the cells to the 
effects of imatinib, suggesting that HAL9 induced restructuring of the BCR-ABL kinase to the 
downregulated conformation that favors drug binding. However, HAL9 did not sensitize TF-1 
cells expressing BCR-ABL T315I to the effects of imatinib. This does not necessarily suggest 
that HAL9 does not induce downregulated conformation of BCR-ABLT315I. However, this may 
suggest that even in the downregulated conformation of the protein the hydrogen bonding 
between the threonine hydroxyl group and imatinib is absolutely necessary for the binding 
stability of imatinib and its effects. This observation could be clarified in the future with 
ponatinib. Ponatinib binds to the ATP binding site and prefers the “DFG-out” conformation, it 
does not require the hydroxyl side chain of threonine for stable binding and it can accommodate 
the isoleucine side chain of T315I mutant. Hence, it is predicted that HAL9 would induce the 
downregulated conformation of the ABL core in BCR-ABL-T315I and would enhance the 
sensitivity to the effects of ponatinib. Interestingly, enhanced SH3:linker interaction dramatically 
sensitized wild-type and T315I BCR-ABL expressing TF-1 cells to the effects of the allosteric 
inhibitors GNF-2 and GNF-5. These results support an allosteric connection between the SH3 
domain, the active site, and the myristic acid binding pocket.  
The results presented in chapter 2 are significant also because they shed light on the role 
of the intermolecular interactions in the ABL core region within the context of constitutively 
active BCR-ABL kinase. Unlike in c-ABL core protein, the role of intermolecular interactions in 
BCR-ABL is less clear and controversial. BCR fusion is sufficient to activate ABL however it 
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does not necessarily displace SH3 and SH2 domains from their regulatory positions. In support 
of this hypothesis, it is well established that imatinib prefers the inactive conformation of the 
kinase domain, and that mutations arising in SH3 and SH2 domains are associated with imatinib 
resistance (Schindler et al., 2000; Sherbenou et al., 2010). These observations support the 
hypothesis that the SH3 and SH2 domains maintain contact with the kinase domain in BCR-
ABL. In addition, Smith et al showed that BCR coiled-coil domain mutations that disrupt BCR-
ABL oligomerization impair its kinase activity. However disruption of SH3:linker interaction 
restores the kinase activity (Smith et al., 2003). This suggests that SH3 maintains negative 
regulatory interaction in BCR-ABL. We have also established that HCK mediated 
phosphorylation of Y89 in the SH3 domain in CML cells correlates with imatinib resistance, 
providing further evidence that SH3:linker interaction maintains its negative regulatory effect in 
BCR-ABL (Pene-Dumitrescu and Smithgall, 2010). The data in the current study clearly show 
that enhancing the SH3:linker interaction (HAL9) in the context of BCR-ABL does not impact 
its kinase or transforming activity yet enhances drug sensitivity to compounds that prefer the 
inactive conformation of the kinase domain.  
On the other hand, a recent structural study showed that the SH2 domain of the c-ABL 
core undergoes major conformational rearrangement and moves from a negative regulatory 
position to a new position that promotes SH2 interaction with the N-lobe of the kinase (Nagar et 
al., 2006). In this “top hat” conformation, the kinase is stabilized in its active state. This highly 
mutated and active ABL protein structure was deduced mostly from small X-ray scattering, and 
though the position of the SH3 domain was not identified, the data suggest that it is also 
displaced. Hence, this study disputes that SH3 and SH2 domains maintain their interaction at the 
back of the active kinase domain. More recently, Grebien et al showed that this “top hat” 
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conformation is critical for maintaining a fully active kinase domain (Grebien et al., 2011). They 
also showed that disruption of the “top hat” conformation by mutations at the SH2:N-lobe 
interface enhances sensitivity to nilotinib which favors the inactive conformation of the kinase. 
However, in the study by Grebien et al, disrupting the SH2:N-lobe interaction, either by mutation 
or by monobody targeting, reduced kinase activity only partially. In light of these observations, 
the data in Chapter 2 dispute the absolute requirement for “top hat” conformation in BCR-ABL 
in order to be “kinase active” and support the concept that BCR-ABL samples multiple active 
states that may be independent from each other.   
In summary, results presented in Chapter 2, showed for the first time that SH3:linker 
interaction is a crucial allosteric regulatory interface controlling the overall dynamics and 
regulation of c-ABL core protein as well as BCR-ABL. Combining biophysical, biochemical and 
biological methodologies and techniques, this study showed that there is allosteric interplay 
between SH3:linker interface, the myristic acid binding pocket and the active site as well as an 
interplay between the SH3:linker interface, the SH2:kinase interface and the active site. This 
work strongly supports that a unique regulatory interaction (SH3:linker) at a distance from the 
active site represents a target for stabilization by small molecules that could then favor a 
downregulated conformation and sensitization to conformationally-selective inhibitors such as 
imatinib and nilotinib. 
4.1.2 BCR-ABL T315I and resistance to Src-selective inhibitor  
In the second aim of my thesis work, I set out to understand the effects of global inhibition of 
SFK activity with the ATP-competitive pyrrolo-pyrimidine inhibitor-A-419259 in cells 
transformed with clinically relevant BCR-ABL mutations. The mutations at residues Y253, 
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E255and T315 are very common and account for about 60-70% of the kinase domain mutations 
in clinically observed imatinib-resistant CML cases (Quintas-Cardama et al., 2009). I observed 
that proliferation of TF-1 cells expressing wild-type and two of the mutant BCR-ABLs (E255V, 
Y253H) is markedly inhibited by A-419259. These results are in agreement with previous work 
from our group that showed inhibition of SFK activity with A-419259 leads to growth arrest and 
apoptosis in primary CML cells and CML cell lines (Pene-Dumitrescu et al., 2008; Wilson et al., 
2002). Surprisingly, neither proliferation nor SFK activity is inhibited by this compound in TF-1 
cells expressing BCR-ABL T315I mutant.  These observations suggest a cross-resistance 
mechanism acquired by BCR-ABL T315I to phosphorylate SFKs and induce drug resistance. 
This unexpected finding has important implications in the use of SFK inhibitors or dual 
ABL/SRC kinase inhibitors as therapeutics in CML. The data in Chapter 3 indicate that the use 
of dual inhibitors that do not overcome T315I activity may not be therapeutically beneficial. 
In support of the cross-resistance mechanism, I show that endogenous LYN and 
exogenously expressed HCK remain phosphorylated in the presence of the inhibitor in cells 
expressing BCR-ABL T315I but not the wild-type oncoprotein. Furthermore, I show that kinase 
dead HCK is strongly phosphorylated by ABL T315I. These observations support a role of ABL 
T315I in phosphorylating SFK members in the presence of Src-selective inhibitors and further 
investigations are necessary to determine whether this cross-resistance mechanism is due to 
differences in the extent of phosphorylation, differential phosphorylation at drug binding sites, 
and/or differential phosphorylation at allosteric sites.  
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4.2 FUTURE DIRECTIONS 
4.2.1 Identify chemical sensitizers of ABL SH3:linker interaction 
The current frontline therapy for CML is imatinib. When imatinib resistance emerges, patients 
are treated with second generation tyrosine kinase inhibitors dasatinib or nilotinib. This strategy 
of sequential therapy can potentially select for cells harboring kinase domain mutations in the 
same allele leading to compound mutations. Compound mutations may be less sensitive to third 
generation drugs and may have different oncogenic potency. To prevent occurrence of 
compound mutations, combination therapy of the aforementioned compounds or a combination 
of ATP-competitive inhibitors with allosteric inhibitors may be initiated at diagnosis. In both 
cases, and upon availability of these drugs, it is necessary to address the tolerability of 
combination of tyrosine kinase inhibitors. Hence, it is crucial to have available allosteric 
inhibitors that could be used in combination with currently available drugs to enhance sensitivity 
and to reduce emergence of resistance. Thus, as a next logical step following the confirmation 
that SH3:linker interface is a key node controlling overall regulation of ABL and BCR-ABL 
kinases, I propose identifying small molecules that reproduce the HAL9 effect. This would 
require a development of an approach amenable to high throughput screening of small molecules 
that would influence the SH3:linker interaction as a new approach to inhibit BCR-ABL activity. 
Previous dynamics studies of the ABL SH3-SH2-linker region showed that the ABL SH3 
domain exhibits a cooperative unfolding-refolding behavior and that this behavior can be 
quenched when bound to the linker or high affinity peptides. This same behavior was observed in 
the presence of the kinase domain in the core of ABL protein. Based on my observations with the 
ABL-HAL system, our group is currently pursuing a fluorescence polarization (FP) assay using 
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ABL SH3-SH2-linker recombinant protein and a fluorescently tagged high affinity peptide 
ligand for the ABL SH3 domain. In the presence of the fluorescently tagged high affinity 
peptide, SH3:peptide interaction will stabilize the fluorescence and result in an FP signal. Thus 
small molecules capable of enhancing SH3:linker interaction would prevent the interaction of 
fluorescently tagged peptide with the SH3 domain and result in diminished  FP signal. Following 
identification of hits with ABL-SH3-SH2-linker protein in FP assay, I propose to test the 
compounds for their ability to sensitize the transiently expressed c-ABL protein in 293T cells to 
inhibition by drugs that prefer the “DFG-out” conformation such as imatinib as well as by 
allosteric inhibitors such as GNF-2/5. Furthermore, to test the effects of the compound in the 
context of BCR-ABL, I propose to study their impact in TF-1 cells expressing wild-type BCR-
ABL as well as clinically relevant mutations. I also propose to investigate the frequency with 
which TF-1 cells expressing wild-type BCR-ABL would become resistant to lead compound 
alone or in combination with ATP-competitive inhibitors such as imatinib. This would be an 
important parameter in considering combination therapy. I also propose to study the mechanism 
of action of the lead compounds that show activity both in vitro and in cell-based assays. One 
way to define the mechanism of SH3:linker enhancement is by determining the X-ray crystal 
structure of NCap-ABL-HAL9 and compare to the structure of wild-type NCap-ABL. I predict 
two possible outcomes: first, the enhanced interaction by HAL9 compared to the wild-type may 
simply result in enhanced packing of SH3 in the back of the kinase. Second, HAL9 may induce 
an alternative downregulatory conformation involving other regions of the protein besides the 
SH3:linker interface.  These studies would help in the understanding of structural differences 
induced by HAL9 modification. One could also crystalize the wild-type protein with the lead 
compound and compare the structural differences with that of the HAL9 structure. Alternatively, 
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instead of investigating differences in a static structural view, I propose studying the impact of 
the lead compound on ABL dynamics using HX MS. Using this methodology, one could 
determine global changes in ABL dynamics as well as regional changes in the presence and 
absence of the compound. I predict that a lead compound that enhances SH3:linker interaction, 
would lengthen SH3 unfolding half-life compared to the protein in the absence of the compound. 
The compound might also reduce deuterium incorporation at the SH2:C-lobe interface and/or the 
N-lobe as shown for the HAL9 core protein.  
4.2.2 Determine the mechanism of acquired Src-kinase resistance to A-419259 in 
the presence of ABL-T315I 
The data presented in chapter 3 of this work supports the use of SFK inhibitors in CML to 
overcome BCR-ABL kinase domain mutations other than T315I. I show that ABL-T315I 
acquires the ability to phosphorylate SFKs and induce drug-resistance. To further investigate the 
suggested mechanism of resistance, I propose to determine whether ABL T315I phosphorylates 
HCK or LYN on sites that are not phosphorylated by wild-type ABL or other imatinib-resistant 
mutants. The prediction is that these sites would either be in direct contact with the drug binding 
site or would allosterically modify the drug binding site. I also propose to investigate whether the 
extent of phosphorylation by wild-type or T315I is different or if both mechanisms (extent of 
phosphorylation and phosphorylation at different sites) contribute to the acquired resistance. To 
test these possibilities, one could purify HCK and LYN recombinant proteins and analyze their 
intact mass in the presence and absence of recombinant wild-type ABL protein and imatinib 
resistant mutants (T315I, E255Vand Y253H). If the cross-resistance mechanism is due to 
differences in the extent of phosphorylation, then it is predicted that T315I would phosphorylate 
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the SFKs more extensively. To determine if the cross-resistance is due to differential 
phosphorylation of SFKs by ABL wild-type versus ABL T315I, it is possible to identify the 
phosphopeptides by mass spectrometry and investigate if the phosphorylated tyrosines map onto 
the drug binding or allosteric site. Following identification of residues involved in differential 
phosphorylation, I propose to substitute these residues with phenylalanine and determine re-
sensitization to the effects of A-419259 in vitro and in cell-based assays. 
Alternatively, the observed mechanism of resistance can be due to cellular mechanisms 
of drug efflux. Expression of P-glycoprotein (Pgp), the ATP-dependent xenobiotic transport 
protein associated with the multi-drug resistant phenotype in many types of tumors, has been 
implicated in the BCR-ABL independent resistance to imatinib (Illmer et al., 2004). This 
observation suggests that the T315I mutation may enhance the ability of BCR-ABL to induce 
Pgp expression as a possible mechanism conferring cross-resistance to A-419259. To rule out the 
involvement of Pgp in the cross-resistance of TF-1 BCR-ABL T315I cells to A-419259, I would 
propose to test the effects of the Pgp blocker verapamil on the sensitivity of TF-1 BCR-ABL 
T315I cells to A-419259 in proliferation assay. The prediction is that, if Pgp is not involved in 
this cross-resistance mechanism, its inhibition would not reverse A-419259 resistance in cells 
expressing BCR-ABL T315I. 
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4.3 CLOSING REMARKS 
The discovery of imatinib and its significant activity in all phases of CML represent a true 
milestone in the cancer therapeutics field. However, despite the impressive success of imatinib, 
clinical relapse due to drug resistance is inevitable. Therefore, new therapies targeting imatinib-
resistant mutants particularly the T315I are needed. The major challenge in developing new 
kinase inhibitors is to achieve highly selective, efficacious inhibitors with minimal potential for 
development of drug resistance. In this context, discovery and design of allosteric inhibitors have 
been gaining much attention. Allosteric inhibitors bind outside the ATP-binding site of a certain 
kinase, exploit a unique regulatory mechanism of the kinase and modulate its activity (Zhang et 
al., 2009).  However, to date there are only handful of well characterized allosteric inhibitors 
such as the MEK1 and MEK2 inhibitor CI-1040 (Ohren et al., 2004), the inhibitor of nuclear 
factor-kB kinase inhibitor BMS-345541(McIntyre et al., 2003) and BCR-ABL inhibitor GNF-2 
(Adrian et al., 2006). Furthermore, identification of allosteric sites in kinases that could be 
targeted remains as much challenging as designing allosteric inhibitors. In this context, the work 
presented in this dissertation identifies SH3:linker interaction as an unique allosteric site that 
induces long range conformational changes in the kinase domain and enhances potency of drugs 
that target the ATP binding site and/or myristic acid binding pocket. This remarkable allosteric 
network linking the SH3 domain, the myristic binding pocket and the active site of the c-ABL 
core was revealed by dynamic studies using HX MS. As such, this work underscores the 
importance of this technique in providing structural basis for biological observations. The data 
presented in this work also revealed a novel finding about the status of the negative regulatory 
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domains in active BCR-ABL kinase. While the dogmatic view supports the displacement of 
these domains from their negative regulatory positions in the active kinase, this work challenges 
that view and clearly shows that enhancing SH3:linker interaction in the context of constitutively 
active BCR-ABL, does not impair the kinase activity yet confers enhanced drug sensitivity. In 
addition, this work also revealed a new mechanism of BCR-ABL T315I-induced resistance to 
drugs that target SFKs. This finding suggests that the use of dual ABL/SRC kinase inhibitors that 
do not overcome T315I activity may not be therapeutically beneficial. Therefore, this study 
supports future drug discovery campaigns to identify allosteric inhibitors that stabilize 
SH3:linker interaction as a new strategy to inhibit wild-type and drug resistant mutants. 
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